中医药每日文献速递

2026 年 8 月 16 日（周六）

检索时间窗口：2026-08-15 00:00 ～ 2026-08-16 24:00（最近 24 小时）

检索数据库：PubMed / Europe PMC / Crossref / OpenAlex / Unpaywall / DOAJ 等

一、检索日期、范围与数据库清单

本期速递的检索与核验工作于 2026-08-16 完成。检索时间窗口为 2026-08-15 00:00 至 2026-08-16 24:00，即“最近 24 小时”内新进入数据库、可稳定访问的中医药及相关医学文献。

1.1 检索式与命中情况

• PubMed 检索式 1：("traditional Chinese medicine"[Title/Abstract]) 且 Entrez 入库日期 2026-08-15 ~ 2026-08-16 → 10 条
• PubMed 检索式 2：acupuncture[Title/Abstract] 同日期窗口 → 12 条
• PubMed 检索式 3："Chinese herbal medicine"[Title/Abstract] OR "herbal medicine"[Title/Abstract] 同窗口 → 6 条
• PubMed 检索式 4：("Chinese medicine"[Title/Abstract] OR "TCM"[Title/Abstract]) 同窗口 → 15 条
• PubMed 检索式 5：中文语种限定 (Language: Chinese) 同窗口 → 0 条（24小时内PubMed无新增中文语种中医药文献）
• 去重后候选：28 篇 → 人工主题相关性筛选 → 精选 20 篇纳入本期速递

1.2 检索源（数据库）清单

1.3 筛选流程与可得性说明

1. ① 通过 5 组检索式在 PubMed 命中候选文献并去重，共得到 28 篇唯一记录；
2. ② 逐一读取题录与摘要，按“中医药相关性 + 学术价值 + 可核验性”精选 20 篇纳入本期；
3. ③ 全部 20 篇的 DOI 均经 Crossref REST API 核验（score=1.0，2026 年注册），PMID/期刊/作者信息以 PubMed 记录为准；
4. ④ 开放获取（OA）状态通过 OpenAlex、PubMed Central（PMC）编号及期刊政策综合判定；
5. ⑤ 由于本期文献均为近 24 小时新增，Europe PMC、Unpaywall 等索引普遍存在 1~3 天延迟，未收录属正常现象，不影响元数据真实性；
6. ⑥ 24 小时窗口内 PubMed 无新增中文语种中医药文献；CNKI/万方/维普在本次检索环境中无法稳定匿名访问（浏览器验证码），故未纳入中文库条目，特此说明。

阅读提示：每篇文献均标注【摘要/全文可得状态】。标有 PMC 编号者为开放获取全文；标注“全文需订阅”者仅可获取题录与摘要。所有英文文献同时给出英文原摘要与中文翻译；中文翻译为忠实直译，如与原文有出入请以英文原摘要为准。

二、文献速递（20 篇精选）

第一部分 · 中药复方与有效成分研究（基础与转化）

第 1 篇（本期第 1 篇）｜从口服汤剂到关节腔内纳米药物：八味调髓汤纳米颗粒负载润滑水凝胶协同治疗膝骨关节炎

英文标题：From oral decoction to intra-articular nanomedicine: Bawei Tiaosui Decoction (BWTSD) nanoparticle-laden lubricating hydrogel for synergistic treatment of knee osteoarthritis

作者：Chen R, Wang X, Chen Y, Li L, Yu S, Wu Z, Jin Y, Wen Z, Huang X, Ma L, Wang S, Liu X, Li L, Tian Y, Jin H, Tong P

期刊：Materials Today Bio（2026）

DOI：10.1016/j.mtbio.2026.103532

PMID：42602932

PMC：PMC13475541

原文链接：https://doi.org/10.1016/j.mtbio.2026.103532

摘要 / 全文可得状态：全文可获取（开放获取，PubMed Central 已收录）

研究问题：探索能否将经典中药复方八味调髓汤（口服汤剂）转化为关节腔注射用纳米水凝胶，实现膝骨关节炎的疾病修饰与协同治疗。

样本与对象：体内、体外实验及离体人软骨外植体；具体动物模型与样本量在摘要中未详述（需查全文）。

研究设计：转化医学实验研究（纳米医学/生物材料）。

使用方法：超分子自组装纳米颗粒 + 交联透明质酸水凝胶复合制备；体内外实验与离体人软骨外植体评价；检测软骨细胞铁死亡及相关通路（GCLM/GPX4、谷胱甘肽合成、脂质过氧化）。

主要结果：BWTS-N@Gel 显著减缓 KOA 进展，机制为抑制软骨细胞铁死亡：维持 GCLM/GPX4 轴、增强谷胱甘肽合成、减轻脂质过氧化并阻止铁介导细胞死亡；同时具备缓释与润滑功能。

局限：摘要未提供动物模型数量、给药途径/剂量的详细比较及长期安全性与临床转化信息，需查阅全文核实。

临床或科研意义：首次将中药复方口服汤剂转化为关节腔纳米递送系统，为“中药+纳米技术”治疗 KOA 提供新范式，兼具机制创新与转化价值。

英文原摘要（English Abstract）

Effective disease-modifying therapies for knee osteoarthritis (KOA) remain elusive. This study developed BWTS-N@Gel, a novel composite comprising supramolecular self-assembled nanoparticles (BWTS-N) derived from the traditional Chinese medicine formula Bawei Tiaosui Decoction, encapsulated within a cross-linked hyaluronic acid hydrogel. BWTS-N features a small particle size facilitating efficient chondrocyte endocytosis, while the hydrogel matrix ensures sustained drug release, and the incorporation of BWTS-N further enhances lubrication, aligning with the "SCALE" therapeutic strategy (Safety, Cartilage protection, Anti-inflammatory, Lubrication, Efficacy). In vivo and in vitro experiments, along with ex vivo human cartilage explant studies, demonstrated that BWTS-N@Gel significantly attenuated KOA progression by suppressing chondrocyte ferroptosis. Mechanistically, the treatment preserved the GCLM/GPX4 axis, thereby enhancing glutathione synthesis, mitigating lipid peroxidation, and preventing iron-mediated cell death. These findings position BWTS-N@Gel as a promising therapeutic candidate that synergizes traditional medicine efficacy with advanced nanotechnology for targeted cartilage protection and joint lubrication in KOA management.

中文摘要翻译

膝骨关节炎（KOA）仍缺乏有效的疾病修饰疗法。本研究开发了 BWTS-N@Gel——一种由传统中药复方八味调髓汤制备的超分子自组装纳米颗粒（BWTS-N）包载于交联透明质酸水凝胶中的新型复合制剂。BWTS-N 粒径小，利于软骨细胞内吞；水凝胶基质保证药物缓释，纳米颗粒的加入进一步增强润滑，契合“SCALE”治疗策略（安全、软骨保护、抗炎、润滑、有效）。体内外实验及离体人软骨外植体研究显示，BWTS-N@Gel 通过抑制软骨细胞铁死亡显著减缓 KOA 进展。机制上，该治疗维持 GCLM/GPX4 轴，从而增强谷胱甘肽合成、减轻脂质过氧化、阻止铁介导的细胞死亡。上述结果使 BWTS-N@Gel 成为将传统药效与先进纳米技术相结合、用于 KOA 靶向软骨保护与关节润滑的有前景的候选治疗制剂。

第 2 篇（本期第 2 篇）｜整合网络药理学、分子对接与实验验证揭示黄连解毒汤治疗细菌性脑膜炎的作用机制

英文标题：Unraveling the therapeutic mechanisms of Huanglian Jiedu Tang in bacterial meningitis: A comprehensive approach integrating network pharmacology, molecular docking, and experimental validation

作者：Xiao Y, Tong X

期刊：Medicine（2026）

DOI：10.1097/MD.0000000000050318

PMID：42601673

PMC：暂无

原文链接：https://doi.org/10.1097/MD.0000000000050318

摘要 / 全文可得状态：开放获取全文（Medicine, Wolters Kluwer, Gold OA）

研究问题：阐明黄连解毒汤治疗细菌性脑膜炎的作用机制，并鉴定其活性成分与关键靶点。

样本与对象：GEO 数据集 GSE40586（生物信息学）；体外细菌性脑膜炎细胞模型（HMC3 小胶质细胞系）。

研究设计：基础研究（网络药理学 + 分子对接 + 实验验证）。

使用方法：网络药理学筛选成分/靶点/通路；分子对接；CCK-8、钠离子通透性、TUNEL、RT-PCR、Western blot、ELISA；GEO 数据分析；共培养模型；MAPK14 敲减验证。

主要结果：495 个 BM 相关基因中 30 个与 HLJDT 靶点重叠；黄柏酮与 MAPK14 结合亲和力最强；黄柏酮或 VX-702 单药均改善细胞活力、抑制凋亡与炎症，联合效果最佳；MAPK14 沉默同样有效，证实该通路的关键作用。

局限：以体外细胞模型为主，缺乏体内动物实验验证；细胞系单一，临床转化需进一步研究。

临床或科研意义：为黄连解毒汤治疗细菌性脑膜炎提供分子药理学基础，提示黄柏酮联合 MAPK14 抑制剂的协同治疗潜力，具有药物开发价值。

英文原摘要（English Abstract）

This study aims to comprehensively elucidate the therapeutic mechanisms of Huanglian Jiedu Tang in bacterial meningitis via an integrated strategy combining network pharmacology, molecular docking, and experimental validation. Network pharmacology was utilized to screen for bioactive constituents, pivotal targets, and associated signaling pathways of HLJDT. The potent candidate Obacunone and its target MAPK14 were prioritized for verification. An in vitro bacterial meningitis cell model was established, followed by therapeutic interventions using Obacunone, the MAPK14 inhibitor VX-702, or their combination. Therapeutic effects were assessed using the CCK-8 assay, sodium ion permeability assays, TUNEL staining, RT-PCR, Western blot, and ELISA. Bioinformatics analysis of the GEO dataset GSE40586 identified 495 BM-related genes, 30 of which intersected with HLJDT targets. GO and KEGG enrichment analyses highlighted biological processes including antibiotic and glucocorticoid responses, as well as transcriptional misregulation and HIF-1 signaling pathways. Molecular docking simulations revealed that Obacunone possessed superior binding affinity to MAPK14. In the BM cell model, treatment with Obacunone or VX-702 alone significantly improved cell viability, attenuated the increased sodium ion permeability, inhibited apoptosis, and suppressed inflammatory cytokine levels. Notably, combination therapy exhibited the most potent synergistic effects. In a bacterial meningitis co-culture model, combined treatment with Obacunone and VX-702, as well as MAPK14 silencing, significantly restored the viability and migratory capacity of HMC3 cells while effectively attenuating early apoptosis. This study delineated the pharmacological underpinnings of HLJDT in BM treatment, identifying it

s active components and targets. Experimental validation confirmed the synergistic action of Obacunone and the MAPK14 inhibitor, providing a robust scientific foundation for future drug development and clinical strategies.

中文摘要翻译

本研究旨在通过整合网络药理学、分子对接与实验验证的策略，全面阐明黄连解毒汤（HLJDT）治疗细菌性脑膜炎（BM）的作用机制。网络药理学用于筛选 HLJDT 的生物活性成分、关键靶点及相关信号通路；优先验证候选成分黄柏酮及其靶点 MAPK14。建立体外细菌性脑膜炎细胞模型，分别用黄柏酮、MAPK14 抑制剂 VX-702 或其联合干预，采用 CCK-8、钠离子通透性、TUNEL 染色、RT-PCR、Western blot 和 ELISA 评估疗效。对 GEO 数据集 GSE40586 的生物信息学分析鉴定出 495 个 BM 相关基因，其中 30 个与 HLJDT 靶点重叠；GO 和 KEGG 富集分析突出了抗生素与糖皮质激素应答、转录失调及 HIF-1 信号通路等生物学过程。分子对接显示黄柏酮对 MAPK14 具有优越的结合亲和力。在 BM 细胞模型中，黄柏酮或 VX-702 单药均显著改善细胞活力、减轻钠离子通透性升高、抑制凋亡并下调炎症细胞因子水平；联合治疗表现出最强的协同效应。在细菌性脑膜炎共培养模型中，黄柏酮联合 VX-702 以及 MAPK14 沉默均显著恢复 HMC3 细胞的活力与迁移能力，同时有效减轻早期凋亡。本研究阐明了 HLJDT 治疗 BM 的药理学基础，鉴定出其活性成分与靶点；实验验证确认黄柏酮与 MAPK14 抑制剂的协同作用，为未来药物开发与临床策略提供了坚实的科学依据。

第 3 篇（本期第 3 篇）｜整合化学轮廓、网络药理学与生物信息学鉴定并定量黄芩汤治疗溃疡性结肠炎的潜在活性成分

英文标题：Identification and quantification of putative active constituents of huangqin decoction for ulcerative colitis treatment through the integration of chemical profiling, network pharmacology, and bioinformatics

作者：Jang S, Kim YJ, Hwang YH

期刊：Frontiers in Chemistry（2026）

DOI：10.3389/fchem.2026.1897628

PMID：42602043

PMC：PMC13473006

原文链接：https://doi.org/10.3389/fchem.2026.1897628

摘要 / 全文可得状态：全文可获取（开放获取，Frontiers）

研究问题：系统鉴定黄芩汤治疗溃疡性结肠炎的潜在活性成分，并建立其定量方法，为质量控制提供依据。

样本与对象：3 批黄芩汤样品；公共数据库与 GEO 数据库的疾病靶基因信息。

研究设计：成分分析与计算药理学研究。

使用方法：LC-MS 化学轮廓分析（鉴定 51 个化合物）；靶点预测；GO/KEGG 富集；PPI 网络；分子对接；15 个潜在活性成分定量。

主要结果：获得 109 个 HQD-UC 共同靶基因；关键靶点包括 NOS2、AHR、MMP3、MMP9、PRKCQ；黄芩苷含量最高；多个化合物-靶点对对接分数低于 -11.0 kcal/mol，预测结合良好。

局限：以计算预测为主，缺乏体内/体外药理验证；活性成分与临床疗效的因果关系尚需实验确证。

临床或科研意义：为黄芩汤的质量控制提供基于活性成分的新评价思路，为后续药理与临床研究奠定科学基础。

英文原摘要（English Abstract）

[INTRODUCTION] Huangqin decoction (HQD), a traditional Chinese medicine prescription, is used to treat gastrointestinal diseases, including ulcerative colitis (UC). However, systematic research on the components of HQD remains insufficient. Therefore, we aimed to perform chemical profiling, network pharmacology, and bioinformatics analyses of HQD to identify candidate constituents potentially associated with UC and to establish a quantitative method for their determination in HQD. [METHODS] Qualitative chemical profiling was performed to identify 51 compounds in HQD, and their potential targets were predicted. UC-related target genes were identified by combining results from public and Gene Expression Omnibus (GEO) databases. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed to investigate the biological processes and signaling pathways associated with UC. Moreover, protein-protein interaction (PPI) analysis was performed. Based on these results, 15 putative active constituents of HQD were selected and quantified. Molecular docking analysis was then performed to evaluate the binding interactions between these compounds and key target proteins. [RESULTS] A total of 947 HQD component-related, 1,868 UC-related, and 2,930 GEO database-related target genes were intersected to obtain 109 common target genes for HQD and UC. GO and KEGG enrichment analyses indicated that these targets were mainly associated with inflammatory and immune-related biological processes and signaling pathways. Among the identified targets, NOS2, AHR, MMP3, MMP9, and PRKCQ were highlighted as potential key targets. The analysis of three batches of HQD samples revealed that baicalin had the highest content. Molecular docking results indicated favor

able predicted interactions between the putative active compounds and core target proteins, with several compound-target pairs exhibiting docking scores below -11.0 kcal/mol. [DISCUSSION] This study not only provides a comprehensive chemical profile of HQD but also presents a new approach for evaluating and managing quality based on putative active constituents. These findings may serve as a scientific basis for further pharmacological and clinical studies.

中文摘要翻译

【引言】黄芩汤（HQD）为传统中药方剂，用于治疗溃疡性结肠炎（UC）等胃肠道疾病，但其成分的系统研究仍不足。本研究旨在对 HQD 进行化学轮廓、网络药理学与生物信息学分析，鉴定与 UC 相关的候选成分，并建立定量测定方法。【方法】定性化学轮廓分析鉴定出 HQD 中 51 个化合物并预测其靶点；结合公共数据库与 GEO 数据库确定 UC 相关靶基因；进行 GO/KEGG 富集分析以探究 UC 相关生物学过程与信号通路，并开展蛋白-蛋白相互作用（PPI）分析。据此筛选出 15 个潜在活性成分并定量；随后用分子对接评价化合物与关键靶蛋白的结合。【结果】将 947 个 HQD 成分相关、1,868 个 UC 相关和 2,930 个 GEO 数据库相关靶基因取交集，获得 109 个 HQD 与 UC 共同靶基因。GO/KEGG 富集显示这些靶点主要涉及炎症与免疫相关生物学过程和信号通路；NOS2、AHR、MMP3、MMP9、PRKCQ 被列为潜在关键靶点。对 3 批 HQD 样品分析显示黄芩苷含量最高。分子对接表明潜在活性化合物与核心靶蛋白间存在有利的预测结合，多个化合物-靶点对的对接分数低于 -11.0 kcal/mol。【讨论】本研究不仅提供了 HQD 的全面化学轮廓，还提出了基于潜在活性成分进行质量评价与管理的新方法，可为后续药理与临床研究提供科学依据。

第 4 篇（本期第 4 篇）｜软坚散结方通过调控 miR-182-5p/EPAS1/EMT 轴抑制肺癌转移

英文标题：Ruanjian Sanjie Formula Affects Metastasis of Lung Cancer by Regulating miR-182-5p/EPAS1/EMT Axis

作者：Wu GJ, Xu L, Yin YN, Zheng ZM, Wang X, Bi L, Wang Q, Yao JL, Yang WX, Jiao LJ

期刊：Chinese Journal of Integrative Medicine（2026）

DOI：10.1007/s11655-026-4157-1

PMID：42603248

PMC：暂无

原文链接：https://doi.org/10.1007/s11655-026-4157-1

摘要 / 全文可得状态：元数据与摘要可得（PubMed）；全文开放获取状态未能在本环境直接核验（出版社页面需登录），请通过 DOI 访问确认

研究问题：探讨软坚散结方抑制肺癌发生与转移的分子机制。

样本与对象：裸鼠 H460 荷瘤模型；H460 与 H1975 肺癌细胞系。

研究设计：体内外实验研究。

使用方法：裸鼠术后转移模型；CCK-8、划痕、Transwell 实验；UPLC-Q-TOF-MS 化学成分分析；网络药理学；qRT-PCR、Western blot；虚拟对接与分子模拟。

主要结果：RJSJ 在体外抑制肺癌细胞增殖/迁移/侵袭，在体内预防复发转移；含 47 个化合物、191 个共同靶点（36 个核心靶点）；下调 miR-182-5p→抑制 EPAS1→抑制 EMT（下调 N-cadherin、MMP2、MMP9、Snail、Twist，上调 E-cadherin）；绿原酸为主要活性成分。

局限：基于动物模型与有限细胞系，剂量-效应关系与临床证据需进一步研究。

临床或科研意义：揭示软坚散结方经 miR-182-5p/EPAS1/EMT 轴抗肺癌转移的新机制，为复方精准应用与药物研发提供依据。

英文原摘要（English Abstract）

[OBJECTIVE] To investigate the specific mechanism by which Ruanjian Sanjie Formula (RJSJ) inhibits the occurrence and metastasis of lung cancer. [METHODS] This study developed an in vivo model using H460 cells in nude mice to investigate postoperative lung cancer metastasis. Two groups received either RJSJ (0.2 mL) or saline to assess RJSJ's anti-cancer effects, including disease-free survival duration, recurrence-free metastasis rate, number of pulmonary metastases, as well as weight and coefficient of major organs. An in vitro study was conducted to evaluate the effects of RJSJ at concentrations ranging from 0 to 500 µg/mL on the proliferation, migration, and invasion capabilities of H460 and H1975 cell lines. These effects were assessed using the CCK-8 assay for cell proliferation, the wound healing assay for cell migration, and the Transwell assay for cell invasion. RJSJ's chemical profile was analyzed via UPLC-Q-TOF-MS, and its mechanism was explored through network pharmacology. Specific microRNAs and their target genes were identified and analyzed using bioinformatics, qRT-PCR, and Western blot to examine RJSJ's impact on metastasis-related genes and proteins during epithelial-mesenchymal transition (EMT). Virtual docking and molecular simulations were used to evaluate interactions between RJSJ compounds and microRNAs. [RESULTS] RJSJ could inhibit the proliferation, migration, and invasion of lung cancer cells in vitro (P<0.05 or P<0.01), and it had also been shown to prevent lung cancer recurrence and metastasis in vivo (P<0.05); it contains 47 chemical compounds that act on 191 common targets, including 36 core targets. It reduced cancer cell proliferation and invasion, downregulated miR-182-5p, thereby regulating its target gene EPAS1, and regulated EMT-relate

d markers by decreasing the expression of N-cadherin, MMP2, MMP9, Snail, and Twist, while increasing the expression of E-cadherin. Chlorogenic acid was identified as the main anti-tumor component due to its strong binding affinity to nucleic acids. [CONCLUSIONS] RJSJ inhibits lung cancer occurrence and metastasis both in vivo and in vitro. Mechanistically, RJSJ suppresses the EMT process by downregulating miR-182-5p and inhibiting EPAS1 expression, thereby restraining lung cancer malignant progression, with chlorogenic acid identified as a key active component.

中文摘要翻译

【目的】探讨软坚散结方（RJSJ）抑制肺癌发生与转移的具体机制。【方法】采用 H460 细胞构建裸鼠体内术后肺癌转移模型，两组分别给予 RJSJ（0.2 mL）或生理盐水，评估无病生存期、无复发转移率、肺转移灶数量及主要脏器重量与系数；体外研究评价 0~500 µg/mL 浓度 RJSJ 对 H460、H1975 细胞增殖（CCK-8）、迁移（划痕）和侵袭（Transwell）的影响；用 UPLC-Q-TOF-MS 分析化学轮廓，网络药理学探索机制，生物信息学、qRT-PCR、Western blot 分析特异性 miRNA 及其靶基因对 EMT 相关基因/蛋白的影响，虚拟对接与分子模拟评价 RJSJ 化合物与 miRNA 的相互作用。【结果】RJSJ 在体外抑制肺癌细胞增殖、迁移与侵袭（P<0.05 或 P<0.01），在体内预防肺癌复发与转移（P<0.05）；其含 47 个化合物，作用于 191 个共同靶点（含 36 个核心靶点）；RJSJ 下调 miR-182-5p，从而调控其靶基因 EPAS1，并调节 EMT 标志物——下调 N-cadherin、MMP2、MMP9、Snail、Twist 表达，上调 E-cadherin 表达；绿原酸因与核酸结合力强被鉴定为主要抗肿瘤成分。【结论】RJSJ 在体内外均抑制肺癌发生与转移；机制上通过下调 miR-182-5p、抑制 EPAS1 表达而抑制 EMT 过程，从而遏制肺癌恶性进展，绿原酸为关键活性成分。

第 5 篇（本期第 5 篇）｜复方苦参注射液通过恢复 AT2 细胞干性与肺泡再生能力减轻放射性肺纤维化

英文标题：Compound Kushen Injection Mitigates Radiation-Induced Pulmonary Fibrosis by Restoring AT2 Cell Stemness and Alveolar Regenerative Capacity

作者：Liu YL, Xu CY, Wang Y, Liang XY, Chen Y

期刊：Chinese Journal of Integrative Medicine（2026）

DOI：10.1007/s11655-026-4159-z

PMID：42603249

PMC：暂无

原文链接：https://doi.org/10.1007/s11655-026-4159-z

摘要 / 全文可得状态：元数据与摘要可得（PubMed）；全文开放获取状态未能在本环境直接核验（出版社页面需登录），请通过 DOI 访问确认

研究问题：验证放射是否经氧化/DNA 损伤损害 AT2 细胞干性，并评价复方苦参注射液（CKI）的保护作用及机制。

样本与对象：小鼠（对照/照射模型/CKI 治疗组）；Sftpc-CreER 与 Rosa26-ZsGreen 谱系示踪小鼠。

研究设计：动物实验研究（转化药理）。

使用方法：CKI 腹腔注射；胸部照射+左肺切除模型；肺功能、组织病理；谱系示踪；免疫荧光（ROS、γH2AX）；AT2 细胞转录组分析。

主要结果：放射诱导 AT2 细胞氧化应激和 DNA 损伤、抑制 Sod1/Parp1、上调 Il6/Tgfb1，导致增殖/分化受损与 Krt8+ 过渡细胞蓄积及纤维化重塑；CKI 显著逆转上述改变，恢复 AT2 干性，改善肺泡再生与纤维化。

局限：动物模型证据；样本量与长期效应需全文确认；临床转化需更多验证。

临床或科研意义：为复方苦参注射液作为上皮定向策略防治放射性肺纤维化提供机制依据，具有放射防护转化价值。

英文原摘要（English Abstract）

[OBJECTIVE] To determine whether radiation directly compromises AT2 cell stemness through oxidative and DNA damage, and to evaluate whether Compound Kushen Injection (CKI) protects AT2 cells, restores alveolar regeneration, and mitigates radiation-induced pulmonary fibrosis. [METHODS] Mice were randomly assigned to a control, irradiated model, or CKI-treated group. CKI (4 mL·kg-1·d-1) was administered intraperitoneally from 3 days before irradiation until the designated endpoints. A thoracic irradiation plus left pneumonectomy model was established to mimic clinical scenarios requiring postoperative lung regeneration. Lung function, histopathology, and compensatory growth of the accessory lobe were assessed. AT2 cells proliferation, differentiation, and transitional Krt8+ accumulation were evaluated using lineage tracing in Sftpc-CreER and Rosa26-ZsGreen mice. Oxidative stress and DNA damage were examined by immunofluorescence. Transcriptomic profiling of sorted lineage-labeled AT2 cells was conducted to identify radiation- and CKI-responsive genes. [RESULTS] Radiation caused marked oxidative stress and γ H2AX-defined DNA damage in AT2 cells, accompanied by suppression of Sod1 and Parp1 and increased Il6 and Tgfb1 expression (P<0.01). These epithelial-intrinsic injuries led to reduced AT2 proliferation, impaired AT2-to-AT1 differentiation, and long-term accumulation of Krt8+ transitional cells. Functionally, irradiation significantly impaired compensatory lung regeneration after pneumonectomy and promoted fibrotic remodeling. CKI markedly alleviated ROS accumulation and DNA damage in AT2 cells, restored Sod1 and Parp1 expression, suppressed inflammatory and profibrotic signaling, rescued AT2 proliferative and differentiative capacities, reduced transitional Krt8+ cell a

ccumulation, and improved both alveolar regeneration and fibrosis (P<0.05). [CONCLUSIONS] CKI preserves epithelial integrity by reducing oxidative and DNA damage, restoring AT2 stemness, and enhancing alveolar repair. These findings provide mechanistic support for CKI as a potential epithelial-directed therapeutic strategy for preventing or treating radiation-induced lung fibrosis.

中文摘要翻译

【目的】明确放射是否通过氧化与 DNA 损伤直接损害 AT2 细胞干性，并评价复方苦参注射液（CKI）能否保护 AT2 细胞、恢复肺泡再生并减轻放射性肺纤维化。【方法】小鼠随机分为对照、照射模型与 CKI 治疗组；CKI（4 mL·kg⁻¹·d⁻¹）自照射前 3 天起腹腔注射至规定终点。建立胸部照射+左肺切除模型模拟需术后肺再生的临床情境；评估肺功能、组织病理与副叶代偿性生长；在 Sftpc-CreER 与 Rosa26-ZsGreen 小鼠中用谱系示踪评价 AT2 细胞增殖、分化及 Krt8+ 过渡细胞蓄积；免疫荧光检测氧化应激与 DNA 损伤；对分选出的谱系标记 AT2 细胞进行转录组分析以鉴定放射与 CKI 应答基因。【结果】放射在 AT2 细胞中诱导显著氧化应激和 γH2AX 定义的 DNA 损伤，伴随 Sod1、Parp1 受抑及 Il6、Tgfb1 表达升高（P<0.01）。这些上皮内在损伤导致 AT2 增殖减少、AT2→AT1 分化受损及 Krt8+ 过渡细胞长期蓄积；功能上显著损害肺切除后代偿性再生并促进纤维化重塑。CKI 显著减轻 AT2 细胞 ROS 蓄积与 DNA 损伤，恢复 Sod1、Parp1 表达，抑制炎症与促纤维化信号，挽救 AT2 增殖与分化能力，减少 Krt8+ 过渡细胞蓄积，并同时改善肺泡再生与纤维化（P<0.05）。【结论】CKI 通过减轻氧化与 DNA 损伤、恢复 AT2 干性、增强肺泡修复来维持上皮完整性，为 CKI 作为预防或治疗放射性肺纤维化的上皮定向治疗策略提供了机制支持。

第 6 篇（本期第 6 篇）｜玉屏风散及其活性代谢产物对肾脏疾病的治疗作用

英文标题：Therapeutic effect of Yupingfeng powder and its bioactive metabolites on renal diseases

作者：Bai Y, Cao Z, Shen Y, Zhang C, Yang X

期刊：Frontiers in Pharmacology（2026）

DOI：10.3389/fphar.2026.1807950

PMID：42602265

PMC：PMC13473425

原文链接：https://doi.org/10.3389/fphar.2026.1807950

摘要 / 全文可得状态：全文可获取（开放获取，Frontiers）

研究问题：系统总结玉屏风散及其活性代谢产物对肾脏疾病的治疗作用与多靶点机制。

样本与对象：综述研究（基于既往已发表文献）。

研究设计：叙述性综述。

使用方法：系统归纳玉屏风散（黄芪、防风、白术）的化学代谢产物、临床应用与药理作用。

主要结果：YPFP 及黄酮、皂苷、多糖、有机酸、内酯、香豆素等活性代谢物具有抗纤维化、抗氧化、免疫调节、抗凋亡、抗炎、抗铁死亡活性，缓解症状并延缓肾病进展。

局限：综述证据等级取决于纳入原始研究质量；未做系统检索与定量合并。

临床或科研意义：为玉屏风散用于肾脏疾病提供系统的药理参考，提示多成分、多靶点的治疗特点。

英文原摘要（English Abstract）

Yupingfeng powder (YPFP), also known as Yupingfeng San, is a traditional Chinese medicine (TCM) formula comprising Astragali Radix, Saposhnikoviae Radix, and Atractylodis Macrocephalae Rhizoma, and is used clinically to treat renal diseases in China. Chemical metabolites in YPFP play a significant role in specific pathophysiologic mechanisms of renal diseases. Chemical metabolites, clinical application, and pharmacology of YPFP were comprehensively summarized. YPFP and its bioactive metabolites (notably flavonoids, saponins, polysaccharides, organic acids, lactones, coumarins) demonstrate significant pharmacological activities in renal diseases, including anti-fibrosis, antioxidant, immunomodulatory, anti-apoptosis, anti-inflammatory, and anti-ferroptosis. These activities alleviate symptoms and delay disease progression. Over recent decades, extensive research has confirmed the therapeutic benefits of YPFP and its bioactive metabolites in the medical intervention of renal diseases. This review systematically investigates the renoprotective effects of YPFP, including its therapeutic effect and multi-target mechanisms, providing a reference for the therapy of renal diseases.

中文摘要翻译

玉屏风散（YPFP，又名玉屏风颗粒）为传统中药复方，由黄芪、防风、白术组成，在中国临床用于治疗肾脏疾病。YPFP 中的化学代谢产物在肾脏疾病特定病理生理机制中发挥重要作用。本文对 YPFP 的化学代谢产物、临床应用与药理学进行了系统总结。YPFP 及其活性代谢产物（尤以黄酮、皂苷、多糖、有机酸、内酯、香豆素为代表）在肾脏疾病中表现出显著的药理学活性，包括抗纤维化、抗氧化、免疫调节、抗凋亡、抗炎与抗铁死亡，可缓解症状并延缓疾病进展。近几十年的广泛研究已证实 YPFP 及其活性代谢产物在肾脏疾病药物治疗中的获益。本综述系统梳理了 YPFP 的肾脏保护作用及其多靶点机制，为肾脏疾病的治疗提供参考。

第二部分 · 针灸与穴位刺激研究

第 1 篇（本期第 7 篇）｜腕踝针超前镇痛对痔切除术后疼痛与尿潴留的影响：一项随机三臂临床试验

英文标题：Effects of Preemptive Analgesia Using Wrist-Ankle Acupuncture on Postoperative Pain and Urinary Retention After Haemorrhoidectomy: A Randomised, Three-Arm, Clinical Trial

作者：He P, Kong J, Peng L, Li Y, Wu D, Ze L

期刊：Journal of Pain Research（2026）

DOI：10.2147/JPR.S618410

PMID：42602644

PMC：PMC13475516

原文链接：https://doi.org/10.2147/JPR.S618410

摘要 / 全文可得状态：全文可获取（开放获取，Dove Medical Press）

研究问题：评估不同时机腕踝针干预对痔切除术后疼痛与尿潴留的疗效，寻找最优镇痛时机。

样本与对象：275 例痔切除术患者（对照组 96、即时镇痛组 89、超前镇痛组 90），2024 年 6 月—2025 年 3 月。

研究设计：前瞻性随机、三臂对照临床试验（注册号 ChiCTR2400084402）。

使用方法：对照组常规护理；即时组首次疼痛（VAS≥1）时于下 6 区行 WAA；超前组术后 1 小时内疼痛发生前行 WAA；留针 6 小时。主要结局 24h 疼痛轨迹、AUC、峰值 VAS；次要结局 POUR、补救镇痛需求。

主要结果：超前组术后 6~24h VAS 持续最低；AUC 较对照组降低 24.5%（44.10 vs 58.44）；峰值 VAS 显著更低（MD=-0.64）；POUR 发生率 14.44% vs 29.17%（OR=0.38）；补救镇痛率降至 13.33%（OR=0.25）；无晕针或皮下出血。

局限：单中心研究；作者指出需多中心试验确认普遍适用性后再常规推广。

临床或科研意义：为腕踝针超前镇痛在肛肠科围手术期多模式镇痛中的应用提供高质量随机对照证据，兼具疗效与安全性。

英文原摘要（English Abstract）

[OBJECTIVE] To evaluate the clinical efficacy of wrist-ankle acupuncture (WAA) at different time points for pain after haemorrhoidectomy and to identify an optimized analgesic strategy. [METHODS] Patients undergoing haemorrhoidectomy between June 2024 and March 2025 were randomly assigned to three groups: control (n=96, conventional care), immediate analgesia (n=89, WAA at lower zone 6 upon first pain [VAS≥1]), and preemptive analgesia (n=90, WAA at lower zone 6 within 1 hour postoperatively before pain onset). Needle retention was 6 hours in both intervention groups. Primary outcomes were 24-hour pain trajectory, cumulative pain burden (AUC), and peak VAS. Secondary outcomes included postoperative urinary retention (POUR) and additional analgesic requirement. [RESULTS] From 6 to 24 hours postoperatively, the preemptive group consistently showed lower VAS scores than the control and immediate groups. Both intervention groups reduced AUC versus control, with the preemptive group achieving the lowest burden (mean AUC=44.10, 95% CI: 39.08-49.11), representing a 24.5% reduction compared with controls (mean AUC=58.44, 95% CI: 53.67-63.21; MD=-14.34). Peak VAS was lower in the preemptive group versus controls (MD=-0.64, P=0.012), but no significant difference was observed between the immediate and control groups (MD=-0.32, P=0.453). Preemptive analgesia significantly reduced POUR incidence (14.44% vs 29.17% in controls; adjusted OR=0.38, 95% CI: 0.17-0.80). Both intervention groups required fewer additional analgesics than controls (35.42% rescue rate), with the greatest reduction in the preemptive group (13.33%; adjusted OR=0.25, 95% CI: 0.11-0.52), followed by the immediate group (22.47%; adjusted OR=0.46, 95% CI: 0.23-0.90). In patients stratified by types of basic analges

ics (Med1 (Flurbiprofen Esters Injection) and Med2 (Parecoxib sodium for injection) subgroups), the preemptive analgesia group consistently showed significantly lower VAS scores (P < 0.01). During the treatment period, no cases of fainting (needle syncope) or subcutaneous haemorrhage occurred in any group. [CONCLUSION] Preemptive WAA within 1 hour postoperatively reduces 24-hour pain, cumulative pain burden, peak VAS, POUR incidence, and additional analgesic requirement, with a favourable safety profile. It represents a promising non-pharmacological adjunct for multimodal perioperative care; however, multi-centre trials are needed to confirm its generalisability before routine adoption. [CHINESE CLINICAL TRIALS REGISTER IDENTIFIER] ChiCTR2400084402.

中文摘要翻译

【目的】评价不同时机腕踝针（WAA）对痔切除术后疼痛的临床疗效，并寻找优化镇痛策略。【方法】2024 年 6 月至 2025 年 3 月接受痔切除术的患者被随机分为三组：对照组（n=96，常规护理）、即时镇痛组（n=89，首次疼痛 VAS≥1 时于下 6 区行 WAA）与超前镇痛组（n=90，术后 1 小时内疼痛发生前行 WAA）。两个干预组均留针 6 小时。主要结局为 24 小时疼痛轨迹、累积疼痛负荷（AUC）与峰值 VAS；次要结局包括术后尿潴留（POUR）与补救镇痛需求。【结果】术后 6~24 小时，超前组 VAS 持续低于对照组与即时组。两干预组 AUC 均低于对照组，超前组负荷最低（AUC=44.10，95%CI 39.08-49.11），较对照组（58.44，95%CI 53.67-63.21）降低 24.5%（MD=-14.34）。超前组峰值 VAS 低于对照组（MD=-0.64，P=0.012），即时组与对照组无显著差异（MD=-0.32，P=0.453）。超前镇痛显著降低 POUR 发生率（14.44% vs 对照组 29.17%，校正 OR=0.38，95%CI 0.17-0.80）。两干预组补救镇痛需求均少于对照组（对照组 35.42%），超前组降幅最大（13.33%，校正 OR=0.25，95%CI 0.11-0.52），即时组次之（22.47%，校正 OR=0.46，95%CI 0.23-0.90）。按基础镇痛药分层（氟比洛芬酯、帕瑞昔布钠亚组）后，超前组 VAS 仍显著更低（P<0.01）。治疗期间各组均未发生晕针或皮下出血。【结论】术后 1 小时内行超前腕踝针可减少 24 小时疼痛、累积疼痛负荷、峰值 VAS、POUR 发生率与补救镇痛需求，安全性良好，是有前景的多模式围手术期非药物辅助手段；但常规应用前需多中心试验确认其外推性。【中国临床试验注册号】ChiCTR2400084402。

第 2 篇（本期第 8 篇）｜针灸对抑郁症患者脑功能的影响：功能性磁共振成像研究的荟萃分析

英文标题：Effects of acupuncture on brain function in patients with depression: A meta-analysis of functional magnetic resonance imaging studies

作者：Zhang J, Shi X, Wang W, Xu K, Li Y, Shi X, Shen Y, Zou Y

期刊：Medicine（2026）

DOI：10.1097/MD.0000000000050185

PMID：42601716

PMC：暂无

原文链接：https://doi.org/10.1097/MD.0000000000050185

摘要 / 全文可得状态：开放获取全文（Medicine, Wolters Kluwer, Gold OA）

研究问题：识别重度抑郁症患者中针灸诱导的脑神经可塑性改变的一致模式，并探索其与临床改善的关系。

样本与对象：7 项随机对照试验、357 例重度抑郁症患者。

研究设计：基于坐标的影像荟萃分析（Meta-analysis of fMRI studies）。

使用方法：静息态 fMRI 指标（ReHo、ALFF/fALFF）；SDM-PSI 算法；留一法敏感性分析；meta 回归；比较针灸类干预与假针/常规治疗。

主要结果：针灸显著增加右侧扣带束与右侧尾状核活动；常规治疗主要增加左侧海马与右侧枕中回；临床改善与左侧小脑可塑性相关，针刺次数与左杏仁核调节呈剂量依赖；针灸组抑郁与焦虑评分降幅更大。

局限：纳入试验数少、针刺方案与 fMRI 指标异质性大、无长期随访、坐标法方法学局限（作者自述）。

临床或科研意义：提示针灸在情绪调节与奖赏处理脑区产生独特可塑性重塑，为针灸治疗抑郁症（尤其快感缺失、情绪失调）提供神经机制证据。

英文原摘要（English Abstract）

[BACKGROUND] Depression poses a major global health burden. Many patients exhibit treatment resistance or experience intolerable side effects with standard therapies. Acupuncture shows promise as an adjunctive therapy for depression, but its neurobiological mechanisms remain incompletely understood. [METHODS] We conducted a coordinate-based meta-analysis to identify consistent patterns of acupuncture-induced neuroplastic changes in patients with major depressive disorder, quantified via resting-state functional magnetic resonance imaging measures of regional homogeneity and amplitude of low-frequency fluctuations (ALFF/fractional ALFF). We synthesized data from 7 randomized controlled trials involving 357 patients with major depressive disorder, comparing acupuncture-based interventions (manual acupuncture, electroacupuncture, or transcutaneous auricular vagus nerve stimulation) against sham acupuncture, conventional treatment, or treatment-as-usual. The seed-based d mapping with permutation of subject images algorithm was used for the imaging meta-analysis, and a leave-one-out sensitivity analysis was performed to assess the robustness of the pooled findings to intervention heterogeneity. [RESULTS] Acupuncture induced significant regional homogeneity /ALFF increases within the right cingulum and right caudate nucleus. In contrast, conventional treatments primarily increased activity in the left hippocampus and right middle occipital gyrus. Meta-regression linked clinical improvement specifically to plasticity changes in the left cerebellum and revealed a dose-dependent relationship between the number of acupuncture sessions and modulation of the left amygdala. Clinically, acupuncture produced significantly greater reductions in depression and anxiety scores than contro

l conditions. [CONCLUSION] Our findings indicate that acupuncture-based interventions elicit a distinct pattern of neuroplastic remodeling, targeting key regions involved in emotion regulation and reward processing, which contrasts with the hippocampal-occipital effects of conventional treatments. The correlation between neuroplastic changes in affective circuits and clinical improvement supports a potential mechanism for acupuncture's efficacy in alleviating core depressive symptoms such as anhedonia and emotional dysregulation. Limitations include the small number of included trials, heterogeneity in acupuncture protocols and resting-state functional magnetic resonance imaging metrics, absence of long-term follow-up data, and methodological caveats inherent to coordinate-based meta-analysis. Future research requires larger, standardized trials with follow-up assessments and integration of neuroimaging with molecular biomarkers to advance personalized neuromodulation strategies for depression.

中文摘要翻译

【背景】抑郁症造成重大全球健康负担，许多患者对标准治疗耐药或出现无法耐受的不良反应。针灸作为抑郁症辅助治疗显示出前景，但其神经生物学机制尚不完全清楚。【方法】研究者开展基于坐标的荟萃分析，以静息态功能磁共振的区域一致性及低频振幅（ALFF/fALFF）为指标，识别重度抑郁症（MDD）患者针灸诱导的神经可塑性改变的一致模式。纳入 7 项随机对照试验、357 例 MDD 患者，比较针灸类干预（手针、电针或经皮耳迷走神经刺激）与假针灸、常规治疗或常规照护。影像荟萃分析采用基于种子点 d mapping 伴被试图像置换（SDM-PSI）算法，并做留一法敏感性分析评估合并结果对干预异质性的稳健性。【结果】针灸显著增加右侧扣带束与右侧尾状核的区域一致性/ALFF；相比之下，常规治疗主要增加左侧海马与右侧枕中回活动。Meta 回归将临床改善与左侧小脑可塑性改变相关联，并揭示针刺次数与左杏仁核调节之间的剂量依赖关系。临床上，针灸组抑郁与焦虑评分的降幅显著大于对照组。【结论】针灸类干预引发一种独特的神经可塑性重塑模式，靶向情绪调节与奖赏处理的关键脑区，与常规治疗的海马-枕叶效应形成对照。情感环路可塑性改变与临床改善的相关性支持针灸缓解快感缺失、情绪失调等核心抑郁症状的潜在机制。局限包括纳入试验数量少、针刺方案与静息态 fMRI 指标异质性大、缺乏长期随访数据以及基于坐标荟萃分析方法学的固有注意事项。未来需要更大样本、标准化、含随访的试验，并将神经影像与分子生物标志物相结合，以推进抑郁症的个体化神经调控策略。

第 3 篇（本期第 9 篇）｜电针改善慢性睡眠剥夺诱导的神经认知损伤：基于海马神经发生与突触可塑性的实验研究

英文标题：Electroacupuncture improves neurocognitive impairment induced by chronic sleep deprivation: an experimental study based on hippocampal neurogenesis and synaptic plasticity

作者：Wu J, Sun J, Li M, Wang H, Lu G, Guo C, Jia K, Zhang M

期刊：Frontiers in Human Neuroscience（2026）

DOI：10.3389/fnhum.2026.1857669

PMID：42602088

PMC：PMC13473373

原文链接：https://doi.org/10.3389/fnhum.2026.1857669

摘要 / 全文可得状态：全文可获取（开放获取，Frontiers）

研究问题：电项针（ENA）是否通过调控海马神经发生与突触可塑性改善慢性睡眠剥夺（CSD）诱导的认知障碍。

样本与对象：雄性 Wistar 大鼠（CSD 模型）。

研究设计：动物实验研究。

使用方法：改良多平台水环境法建模；电针/假电针双侧风池、供血穴（20min/日×14 天）；Morris 水迷宫、新物体识别；IF/WB（DCX、Ki-67）；Golgi-Cox 染色与透射电镜。

主要结果：CSD 大鼠海马 DCX、Ki-67 显著下降，DG 区突触密度/突触后致密物变薄、突触间隙增宽、树突棘（尤其蘑菇型棘）密度降低；ENA 改善空间与再认记忆并逆转上述神经发生与突触可塑性异常。

局限：动物模型（雄性大鼠），尚不能直接外推至临床；机制通路有待进一步明确。

临床或科研意义：为电项针治疗慢性睡眠剥夺认知障碍提供机制证据，提示其重建海马神经回路的潜能。

英文原摘要（English Abstract）

[OBJECTIVE] Normal sleep rhythms are crucial for hippocampus-dependent advanced cognitive functions. Chronic sleep deprivation (CSD) impairs hippocampal neurogenesis and structure, leading to neurocognitive deficits. Electro-nape-acupuncture (ENA) at bilateral Fengchi (GB20) and Gongxue (Extra) is a specialized acupuncture technique for treating insomnia, amnesia, and other brain-originated diseases. This study aims to investigate whether ENA improves CSD-induced cognitive impairment by regulating neurogenesis and synaptic plasticity in the hippocampus. [METHODS] The modified multi-platform water environment method was used to establish the CSD model. Electroacupuncture or sham electroacupuncture was used to treat bilateral cervical acupoints (Fengchi and Gongxue) for 20 min, once a day for 14 days. The Morris water maze experiment evaluated spatial learning and memory in rats, and the new object recognition experiment evaluated recognition memory. Immunofluorescence (IF) staining and Western Blot (WB) were used to detect the expression levels of the hippocampal neurogenesis markers, doublecortin (DCX) and Ki-67. Golgi-Cox staining and transmission electron microscopy were used to observe the changes in neurons and synaptic plasticity in the dentate gyrus (DG) of the hippocampus. [RESULTS] Neurocognitive impairment induced by CSD is associated with abnormal changes in hippocampal neurogenesis and synaptic plasticity. The results of IF and WB showed that the protein expressions of DCX and Ki-67 in the hippocampus of CSD rats were significantly decreased. Transmission electron microscopy revealed that in the DG region of the hippocampus of CSD rats, the synaptic density and the thickness of the postsynaptic density membrane decreased, while the synaptic cleft width increa

sed. Golgi staining showed that the density of dendritic spines in the DG area of the hippocampus in CSD rats decreased significantly, especially mushroom-shaped dendritic spines. ENA can enhance spatial learning and memory, as well as recognition memory, induced by CSD, and effectively reverse the abnormal changes in neurogenesis and synaptic plasticity in the DG region of the hippocampus. [CONCLUSION] In male Wistar rats, ENA improves neurocognitive function by promoting neurogenesis in the hippocampal dentate gyrus and restoring synaptic plasticity, thereby reconstructing neural memory circuits. ENA therapy offers a new strategy for treating cognitive impairments related to chronic sleep deprivation in males, and holds potential significance for the clinical management of cognitive impairment diseases.

中文摘要翻译

【目的】正常睡眠节律对海马依赖的高级认知功能至关重要。慢性睡眠剥夺（CSD）损害海马神经发生与结构，导致神经认知缺陷。双侧风池（GB20）与供血（Extra）穴位的电项针（ENA）是治疗失眠、健忘等脑源性疾病的特色针法。本研究旨在探讨 ENA 是否通过调控海马神经发生与突触可塑性改善 CSD 诱导的认知障碍。【方法】采用改良多平台水环境法建立 CSD 模型；对大鼠双侧颈项部穴位（风池、供血）行电针或假电针，每次 20 分钟、每日 1 次、连续 14 天。Morris 水迷宫评估空间学习与记忆，新物体识别实验评估再认记忆；免疫荧光与 Western blot 检测海马神经发生标志物双皮质素（DCX）与 Ki-67 的表达；Golgi-Cox 染色与透射电镜观察海马齿状回（DG）神经元与突触可塑性变化。【结果】CSD 诱导的神经认知损伤与海马神经发生和突触可塑性异常相关。IF 与 WB 显示 CSD 大鼠海马 DCX、Ki-67 蛋白表达显著下降；透射电镜显示 DG 区突触密度与突触后致密物膜厚度下降、突触间隙增宽；Golgi 染色显示 DG 区树突棘密度显著下降，尤以蘑菇型树突棘明显。ENA 可增强 CSD 大鼠的空间学习记忆与再认记忆，并有效逆转 DG 区神经发生与突触可塑性的异常变化。【结论】在雄性 Wistar 大鼠中，ENA 通过促进海马齿状回神经发生与恢复突触可塑性改善神经认知功能，从而重建神经记忆回路。ENA 为治疗慢性睡眠剥夺相关认知障碍提供了新策略，对认知障碍疾病的临床管理具有潜在意义。

第 4 篇（本期第 10 篇）｜灵龟探穴针刺联合体外冲击波治疗梨状肌综合征的临床疗效：一项前瞻性对照临床研究

英文标题：Clinical efficacy of Linggui Tanxue acupuncture combined with extracorporeal shock wave therapy for piriformis syndrome: a prospective comparative clinical study

作者：Xue C, Ma J, Wei L, Liu S

期刊：Frontiers in Medicine（2026）

DOI：10.3389/fmed.2026.1897807

PMID：42602886

PMC：PMC13475342

原文链接：https://doi.org/10.3389/fmed.2026.1897807

摘要 / 全文可得状态：全文可获取（开放获取，Frontiers）

研究问题：评估灵龟探穴针刺联合体外冲击波治疗梨状肌综合征的短期疗效与安全性。

样本与对象：60 例梨状肌综合征患者（35~45 岁），联合组 30、对照组 30。

研究设计：前瞻性、随机数字表分配、评估者设盲的对照临床研究（探索性）。

使用方法：对照组 ESWT 单用；联合组灵龟探穴针刺+ESWT；疗程 2 周；盲法评估 VAS、超声梨状肌厚度、疗效等级与不良事件。

主要结果：2 周后两组均显著改善；联合组治疗后 VAS 更低（1.44 vs 3.57，MD=-2.12）、梨状肌厚度更薄（9.04 vs 12.16 mm，MD=-3.13 mm）；总有效率 86.7% vs 46.7%；无严重不良事件。

局限：未前瞻性注册、无预设统计分析计划、无正式样本量计算、仅 2 周随访（作者自述，属探索性研究）。

临床或科研意义：初步提示灵龟探穴针刺联合 ESWT 短期疗效更优，为针刺+物理治疗联合干预肌肉骨骼疾病提供临床依据，但需更严格设计的研究证实。

英文原摘要（English Abstract）

[OBJECTIVE] To evaluate the short-term clinical efficacy and safety of Linggui Tanxue acupuncture combined with extracorporeal shock wave therapy (ESWT) in patients with piriformis syndrome (PS). [METHODS] Sixty patients with PS aged 35 to 45 years were prospectively allocated using a random-number table into a control group receiving ESWT alone and a combined-treatment group receiving Linggui Tanxue acupuncture followed by ESWT, with 30 patients in each group. The treatment course lasted 2 weeks. Visual analogue scale (VAS) pain scores, musculoskeletal ultrasound (MSUS)-measured piriformis muscle thickness, clinical efficacy category, and adverse events were evaluated. Pain assessment and ultrasound measurement were performed by assessors blinded to treatment allocation. Because the study was not prospectively registered and no predefined statistical analysis plan or formal sample size calculation was established before initiation, the analysis should be interpreted as exploratory. [RESULTS] Baseline sex distribution, age, disease duration, VAS scores, and piriformis muscle thickness were comparable between groups (all p > 0.05). After 2 weeks, both groups showed significant reductions in VAS scores and piriformis muscle thickness (both p < 0.001). The combined-treatment group showed significantly greater improvement than the ESWT-alone control group in the two continuous outcomes: post-treatment VAS score was lower in the combined-treatment group (1.44 ± 0.10 vs. 3.57 ± 0.17; mean difference, -2.12; 95% CI, -2.20 to -2.05; p < 0.001), and post-treatment piriformis thickness was also lower (9.04 ± 0.16 mm vs. 12.16 ± 0.25 mm; mean difference, -3.13 mm; 95% CI, -3.23 to -3.02; p < 0.001). The combined-treatment group also had a significantly higher total effective rate

than the control group (86.7% vs. 46.7%; Fisher exact p = 0.002), but this categorical outcome was considered supportive and should be interpreted cautiously. No serious adverse events occurred. [CONCLUSION] Linggui Tanxue acupuncture combined with ESWT may provide greater short-term pain relief and greater ultrasound-measured improvement in piriformis muscle thickness than ESWT alone in patients with PS. The findings are encouraging but not definitive because of the absence of prospective registration, lack of a predefined statistical analysis plan, lack of formal sample size calculation, and the short 2-week follow-up period. Larger prospectively registered multicenter studies with predefined statistical analysis plans, formal sample size calculations, and longer follow-up are warranted.

中文摘要翻译

【目的】评估灵龟探穴针刺联合体外冲击波（ESWT）治疗梨状肌综合征（PS）的短期临床疗效与安全性。【方法】60 例 35~45 岁 PS 患者按随机数字表前瞻性分为 ESWT 单用对照组与灵龟探穴针刺后行 ESWT 的联合组，每组 30 例，疗程 2 周。评价视觉模拟评分（VAS）、肌骨超声（MSUS）测量的梨状肌厚度、临床疗效等级与不良事件；疼痛评估与超声测量由对分组设盲的评估者执行。因研究未前瞻性注册、未预设统计分析计划、未进行正式样本量计算，结果应视为探索性。【结果】两组基线性别、年龄、病程、VAS 与梨状肌厚度均可比（均 p>0.05）。2 周后两组 VAS 与梨状肌厚度均显著下降（均 p<0.001）。联合组在两个连续结局上均显著优于 ESWT 单用组：治疗后 VAS 更低（1.44±0.10 vs 3.57±0.17，均差 -2.12，95%CI -2.20~-2.05，p<0.001），梨状肌厚度更薄（9.04±0.16 mm vs 12.16±0.25 mm，均差 -3.13 mm，95%CI -3.23~-3.02，p<0.001）。联合组总有效率显著更高（86.7% vs 46.7%，Fisher 精确检验 p=0.002），但该分类结局视为支持性证据，应谨慎解读。未发生严重不良事件。【结论】在 PS 患者中，灵龟探穴针刺联合 ESWT 可能比 ESWT 单用提供更优的短期疼痛缓解和超声测量的梨状肌厚度改善。由于缺乏前瞻性注册、预设统计分析计划、正式样本量计算以及 2 周短随访，结果令人鼓舞但非决定性；需开展更大样本、前瞻性注册、含预设分析与正式样本量计算并延长随访的多中心研究。

第 5 篇（本期第 11 篇）｜退行性腰椎管狭窄症神经源性跛行患者针刺应答的预后因素与疗效修饰因素：随机对照试验的二次分析

英文标题：Prognostic Factors and Treatment Effect Modifiers for Acupuncture Response in Patients with Neurogenic Claudication of Degenerative Lumbar Spinal Stenosis: Secondary Analysis of a Randomized Controlled Trial

作者：Shen X, Gao S, Liang J, Fang J, Chen H, Wang W, Liu Z

期刊：Journal of Pain Research（2026）

DOI：10.2147/JPR.S623831

PMID：42602926

PMC：PMC13475425

原文链接：https://doi.org/10.2147/JPR.S623831

摘要 / 全文可得状态：全文可获取（开放获取，Dove Medical Press）

研究问题：识别退行性腰椎管狭窄症伴神经源性跛行患者对针刺应答的预后因素与疗效修饰因素，以指导患者选择。

样本与对象：196 例 DLSS 患者随机化，178 例完成 6 周干预，其中 119 例为应答者。

研究设计：多中心随机对照试验的二次分析（logistic 回归）。

使用方法：应答定义：改良 RMDQ 自基线至第 6 周下降≥2 分；对 17 项基线特征行 logistic 回归分析。

主要结果：治疗分配（OR=2.10）、年龄（OR=1.07）、SSSQ 症状严重度（OR=1.13）与应答正相关；当前发作病程较短者可能从针刺获益更多（OR=0.94）。

局限：二次分析性质、样本量有限；应答定义基于单一问卷；需前瞻性验证。

临床或科研意义：为 DLSS 患者针刺治疗的个体化患者选择提供初步循证依据，有助于临床决策。

英文原摘要（English Abstract）

[PURPOSE] Acupuncture has shown its efficacy in improving pain-specific disability among patients with degenerative lumbar spinal stenosis (DLSS) who predominantly present with neurogenic claudication pain symptoms. It is still unclear which group of the patients have better response to acupuncture. This secondary analysis of a randomized controlled trial aimed to identify potential prognostic factors and treatment effect modifiers of response to acupuncture in DLSS patients with neurogenic claudication. [PATIENTS AND METHODS] A secondary analysis was conducted based on a multi-center randomized controlled trial, where 196 DLSS patients were randomized to acupuncture or sham acupuncture and 178 completed the 6-week intervention. Responders were defined by a 2-point reduction in the modified Roland-Morris Disability Questionnaire (RMDQ) score from baseline to week 6. Baseline characteristics were summarized using descriptive statistics. Seventeen baseline characteristics were considered as potential prognostic factors of response and subjected to logistic regression analysis. [RESULTS] Among the 178 patients included in this secondary analysis, 119 were defined as responders. Treatment assignment (OR 2.0977; 95% CI 1.0300 to 4.2721; p = 0.0412), age (OR 1.0684, 95% CI 1.0176 to 1.1217; p = 0.0078), and Swiss Spinal Stenosis Questionnaire (SSSQ) symptom severity score (OR 1.1270; 95% CI 1.0077 to 1.2606; p = 0.0363) were positively associated with patient response. Patients with a shorter duration of the current episode (OR 0.9384; 95% CI 0.9020 to 0.9764; p = 0.0017) might specifically benefit more from acupuncture. [CONCLUSION] DLSS patients with receiving acupuncture, older age, higher SSSQ symptom severity score, and shorter duration of current episode may be more lik

ely to be responder. Duration of current episode modifies the response of acupuncture. These findings provide preliminary evidence to inform patient selection and warrant validation in future studies.

中文摘要翻译

【目的】针灸已被证实可改善以神经源性跛行疼痛为主要表现的退行性腰椎管狭窄症（DLSS）患者的疼痛特异性功能障碍，但哪些患者对针灸应答更佳仍不明确。本随机对照试验的二次分析旨在识别 DLSS 伴神经源性跛行患者对针灸应答的潜在预后因素与疗效修饰因素。【对象与方法】基于一项多中心随机对照试验进行二次分析：196 例 DLSS 患者被随机分配至针灸或假针灸组，178 例完成 6 周干预。应答定义为改良 Roland-Morris 残疾问卷（RMDQ）评分自基线至第 6 周下降≥2 分。采用描述性统计汇总基线特征，将 17 项基线特征作为潜在预后因素进行 logistic 回归分析。【结果】纳入二次分析的 178 例患者中，119 例被定义为应答者。治疗分配（OR=2.0977，95%CI 1.0300-4.2721，p=0.0412）、年龄（OR=1.0684，95%CI 1.0176-1.1217，p=0.0078）与瑞士脊柱狭窄问卷（SSSQ）症状严重度评分（OR=1.1270，95%CI 1.0077-1.2606，p=0.0363）与应答正相关；当前发作病程较短者（OR=0.9384，95%CI 0.9020-0.9764，p=0.0017）可能从针灸中获益更多。【结论】接受针灸、年龄较大、SSSQ 症状严重度评分较高、当前发作病程较短的 DLSS 患者更可能是应答者；当前发作病程修饰针灸的应答。这些发现为患者选择提供了初步证据，有待未来研究验证。

第 6 篇（本期第 12 篇）｜针刺调控创伤性脑损伤中的线粒体稳态：现有证据、机制假说与转化挑战

英文标题：Acupuncture regulates mitochondrial homeostasis in traumatic brain injury: current evidence, mechanistic hypotheses, and translational challenges

作者：Li G, Cao L, Zhao S, Fang Y, Peng Z, Deng F, Qing P, Zhu M, Zhang Y, Lin S

期刊：Chinese Medicine（2026）

DOI：10.1186/s13020-026-01481-2

PMID：42601636

PMC：暂无

原文链接：https://doi.org/10.1186/s13020-026-01481-2

摘要 / 全文可得状态：全文可获取（开放获取，BMC/Springer Nature）

研究问题：系统梳理针刺（尤其电针）对创伤性脑损伤后线粒体稳态调控的现有证据、机制假说与转化挑战。

样本与对象：综述研究（基于临床前与机制研究文献）。

研究设计：叙述性综述。

使用方法：从结构稳态、数量稳态、功能/代谢稳态三个层面归纳，区分直接证据、间接证据与假说机制。

主要结果：临床前证据提示针刺可能通过线粒体动力学、生物发生、线粒体自噬、能量代谢、氧化应激、钙信号、膜电位、凋亡、线粒体转移等多维机制影响 TBI 后线粒体稳态；但直接 TBI 特异性证据有限。

局限：直接证据不足，多数机制仍处假说阶段，需进一步验证（作者自述）。

临床或科研意义：为针刺治疗 TBI 的机制研究提供系统框架，明确当前证据强度与未来研究方向。

英文原摘要（English Abstract）

[BACKGROUND] Traumatic brain injury (TBI) is associated with high morbidity, disability, and long-term neurological sequelae. Mitochondrial dysfunction is a central component of secondary injury after TBI, contributing to impaired energy metabolism, oxidative stress, calcium dysregulation, neuroinflammation, and neuronal apoptosis. [MAIN BODY] This review summarizes current evidence regarding acupuncture-mediated regulation of mitochondrial homeostasis after TBI, focusing on structural homeostasis, quantitative homeostasis, and functional/metabolic homeostasis. We distinguish direct evidence from TBI models, indirect evidence from related brain injury models, and hypothesis-generating mechanisms. Particular attention is given to mitochondrial dynamics, mitochondrial biogenesis, mitophagy, energy metabolism, oxidative stress, calcium signaling, mitochondrial membrane potential, apoptosis, intercellular mitochondrial transfer, and putative upstream neural and humoral pathways. [CONCLUSION] Current preclinical evidence suggests that acupuncture, particularly electroacupuncture, may influence mitochondrial homeostasis after TBI through multidimensional and context-dependent mechanisms. However, direct TBI-specific evidence remains limited, and several proposed mechanisms require further validation before acupuncture-mediated mitochondrial regulation can be considered a clinically established therapeutic strategy.

中文摘要翻译

【背景】创伤性脑损伤（TBI）致残率与死亡率高，并伴长期神经后遗症。线粒体功能障碍是 TBI 后继发性损伤的核心环节，参与能量代谢受损、氧化应激、钙调节紊乱、神经炎症与神经元凋亡。【主体】本综述总结了针刺介导的 TBI 后线粒体稳态调控的现有证据，聚焦结构稳态、数量稳态与功能/代谢稳态三个层面，并区分来自 TBI 模型的直接证据、来自相关脑损伤模型的间接证据与产生假说的机制。特别关注线粒体动力学、线粒体生物发生、线粒体自噬、能量代谢、氧化应激、钙信号、线粒体膜电位、凋亡、线粒体细胞间转移及可能的上游神经与体液通路。【结论】现有临床前证据提示针刺（尤其电针）可能通过多维、情境依赖的机制影响 TBI 后线粒体稳态；但直接的 TBI 特异性证据仍有限，多个拟议机制需进一步验证，方能将针刺介导的线粒体调控视为临床上确立的治疗策略。

第 7 篇（本期第 13 篇）｜电针作为贝尔面瘫的辅助治疗：一例病例报告

英文标题：Electroacupuncture as an Adjunctive Therapy for Bell's Palsy: A Case Report

作者：Torres MJS, Lai I

期刊：Cureus（2026）

DOI：10.7759/cureus.112675

PMID：42602544

PMC：PMC13475030

原文链接：https://doi.org/10.7759/cureus.112675

摘要 / 全文可得状态：全文可获取（开放获取，Cureus）

研究问题：报告电针作为迟发型贝尔面瘫辅助治疗的一例病例，探讨其可行性。

样本与对象：1 例 81 岁男性急性左侧下运动神经元型面瘫患者（贝尔面瘫）。

研究设计：病例报告。

使用方法：起病第 17 天起低频电刺激针刺（面部与颅部穴位），每周 2 次×7 周，配合居家保守干预；House-Brackmann 分级评价。

主要结果：面神经功能由就诊时 House-Brackmann Ⅳ级改善至Ⅰ~Ⅱ级，治疗过程中无不良事件报告。

局限：单病例设计，无法排除自愈性恢复；缺乏对照与长期随访。

临床或科研意义：提示电针在就诊延迟、预后不利的贝尔面瘫患者中可能作为辅助治疗，为后续前瞻性研究提供病例基础。

英文原摘要（English Abstract）

Bell's palsy is the most common cause of acute unilateral lower motor neuron-type facial nerve paralysis and is generally managed with early administration of corticosteroids, with or without antiviral therapy. Although most patients experience substantial recovery, a clinically meaningful subset-including older adults, individuals with delayed presentation, and those with comorbid medical conditions-may be left with incomplete resolution, with persistent facial weakness, asymmetry, or synkinesis. Electroacupuncture (EA) has been proposed as an adjunctive treatment modality for facial nerve recovery, with hypothesized mechanisms including enhanced neuromuscular activation, improved regional blood flow, modulation of local inflammatory responses, and facilitation of peripheral nerve regeneration. However, robust clinical evidence and detailed case-based documentation remain limited. We report the case of an 81-year-old male patient who presented with acute left-sided lower motor neuron-type facial paralysis. The diagnosis was consistent with Bell's palsy, after a cerebrovascular accident was excluded, and neuroimaging demonstrated no acute intracranial pathology. An integrative treatment approach incorporating acupuncture with low-frequency electrical stimulation was initiated on day 17 post-onset, targeting facial and cranial acupoints. EA treatment was administered twice weekly for seven weeks and was supplemented with conservative home-based interventions. Facial nerve function improved from House-Brackmann Grade IV at presentation to Grade I-II. While this case suggests that EA may have a role as an adjunctive therapy in Bell's palsy, including in patients with delayed presentation and less favorable prognostic features, its interpretation is limited by the single-ca

se design and the known potential for spontaneous recovery. Accordingly, controlled prospective studies are warranted to further evaluate the efficacy, optimal timing, and clinical utility of EA in the management of acute facial nerve paralysis.

中文摘要翻译

贝尔面瘫是急性单侧下运动神经元型面神经麻痹最常见的原因，通常以早期糖皮质激素±抗病毒治疗为主。多数患者可显著恢复，但仍有临床意义可观的一部分——包括老年人、就诊延迟者及合并基础疾病者——可能恢复不完全，遗留持续面肌无力、不对称或联动运动。电针（EA）被提出作为促进面神经恢复的辅助治疗手段，假说机制包括增强神经肌肉激活、改善局部血流、调节局部炎症反应及促进周围神经再生，但可靠的临床证据与详尽的病例记录仍有限。本文报告一例 81 岁男性，表现为急性左侧下运动神经元型面瘫，排除脑血管事件并经神经影像证实无急性颅内病变后诊断为贝尔面瘫。起病第 17 天开始采用针刺联合低频电刺激的综合治疗，选取面部及颅部穴位；EA 每周 2 次、持续 7 周，并辅以保守的家庭干预。面神经功能由就诊时 House-Brackmann Ⅳ级改善至Ⅰ~Ⅱ级。本病例提示 EA 在贝尔面瘫中可能具有辅助治疗作用，包括对就诊延迟、预后特征不利的患者；但解读受单病例设计及自愈可能性的限制。因此，需开展前瞻性对照研究以进一步评价 EA 治疗急性面神经麻痹的疗效、最佳时机与临床应用价值。

第三部分 · 中医药临床循证与评价

第 1 篇（本期第 14 篇）｜中医药减少老年重症社区获得性肺炎患者的治疗失败：一项随机对照试验的事后分析

英文标题：Chinese Medicine Reduces Treatment Failure in Elderly Patients with Severe Community-Acquired Pneumonia: A Post-Hoc Analysis of a Randomized Controlled Trial

作者：Wang HF, Zhang K, Xie K, Yang H, Ji WS, Li JS

期刊：Chinese Journal of Integrative Medicine（2026）

DOI：10.1007/s11655-026-3960-z

PMID：42603247

PMC：暂无

原文链接：https://doi.org/10.1007/s11655-026-3960-z

摘要 / 全文可得状态：元数据与摘要可得（PubMed）；全文开放获取状态未能在本环境直接核验（出版社页面需登录），请通过 DOI 访问确认

研究问题：探讨基于辨证论治的中医药联合常规治疗对老年（≥60 岁）重症社区获得性肺炎患者的疗效与安全性。

样本与对象：128 例老年重症 CAP 患者（ITT：联合组 67、常规组 61）。

研究设计：多中心随机安慰剂对照试验的事后分析（Post-hoc analysis）。

使用方法：常规治疗+辨证 CM 或 CM 安慰剂，28 天；主要结局治疗失败率；次要 28/90 天死亡率、临床稳定时间与稳定率、住院时间、不良事件。

主要结果：联合组治疗失败率 20.9% vs 39.3%（差 18%，P<0.05）；28 天死亡率 19.4% vs 36.1%；临床稳定时间 HR=2.44；临床稳定率 64.2% vs 34.4%；不良事件两组相似。

局限：事后分析性质；样本量有限（n=128）；非预先设计的主要分析。

临床或科研意义：为辨证中医药联合常规治疗老年重症 CAP 提供有效性（降低治疗失败）与安全性的高质量证据，支持中西医结合治疗重症感染。

英文原摘要（English Abstract）

[OBJECTIVE] To explore the effectiveness and safety of Chinese medicine (CM) treatment based on pattern identification (PI) in elderly patients (⩾ 60 years) with severe community-acquired pneumonia (CAP). [METHODS] This post hoc analysis was based on a multicenter, randomized, placebo-controlled trial. Elderly patients with severe CAP were randomly assigned to receive either conventional medicine plus CM placebo (conventional group) or conventional medicine combined with CM treatment based on PI (combination group) for a 28-d treatment period. The primary outcome was the rate of treatment failure. Secondary outcomes included 28- and 90-d mortality, time to clinical stability, rate of clinical stability, length of hospital stay, and adverse events. [RESULTS] A total of 128 elderly patients with severe CAP were included in the intention-to-treat population, comprising 67 patients in the combination group and 61 in the conventional group. The rate of treatment failure was lower in the combination group than in the conventional group (20.9% vs. 39.3%), with a between-group difference of 18% [95% confidence interval (CI), 0.03-0.34; P<0.05]. The 28-d mortality in the combination group was lower than that in the conventional group (19.4% vs. 36.1%), with a difference of 17% (95% CI, 0.01-0.32; P<0.05). Time to clinical stability was significantly shorter in the combination group than in the conventional group, with a Hazard ratio of 2.44 (95% CI, 1.44-4.14; P<0.01). The rate of clinical stability was higher in the combination group than in the conventional group (64.2% vs. 34.4%), with the between-group difference was 30% (95% CI, 0.13-0.46; P<0.01). Similar results were observed in the per-protocol population. The incidence of adverse events was similar between combination a

nd conventional groups. [CONCLUSION] The combination of conventional medicine with CM treatment based on PI was effective and safe in reducing treatment failure among elderly patients with severe CAP compared with conventional medicine alone.

中文摘要翻译

【目的】探讨基于辨证论治的中医药（CM）治疗对≥60 岁老年重症社区获得性肺炎（CAP）患者的有效性与安全性。【方法】本事后分析基于一项多中心、随机、安慰剂对照试验。老年重症 CAP 患者随机接受常规治疗+CM 安慰剂（常规组）或常规治疗+辨证 CM 治疗（联合组），治疗 28 天。主要结局为治疗失败率；次要结局包括 28 天与 90 天死亡率、临床稳定时间、临床稳定率、住院时间与不良事件。【结果】意向性治疗人群共纳入 128 例老年重症 CAP 患者，其中联合组 67 例、常规组 61 例。联合组治疗失败率低于常规组（20.9% vs 39.3%），组间差异 18%（95%CI 0.03-0.34，P<0.05）；联合组 28 天死亡率更低（19.4% vs 36.1%），差异 17%（95%CI 0.01-0.32，P<0.05）；临床稳定时间显著缩短，HR=2.44（95%CI 1.44-4.14，P<0.01）；临床稳定率更高（64.2% vs 34.4%），组间差异 30%（95%CI 0.13-0.46，P<0.01）。符合方案人群中结果相似。两组不良事件发生率相近。【结论】与常规治疗单用相比，常规治疗联合辨证 CM 治疗能有效且安全地降低老年重症 CAP 患者的治疗失败。

第 2 篇（本期第 15 篇）｜中药治疗卒中后疲劳的定量分析：荟萃分析与用药规律研究

英文标题：Quantitative analysis of Chinese herbal medicine for post-stroke fatigue: a meta-analysis and medication pattern study

作者：Liu Y, Wang J, Wu X, Wang Y

期刊：Frontiers in Pharmacology（2026）

DOI：10.3389/fphar.2026.1880065

PMID：42602211

PMC：PMC13473405

原文链接：https://doi.org/10.3389/fphar.2026.1880065

摘要 / 全文可得状态：全文可获取（开放获取，Frontiers）

研究问题：整合荟萃分析与用药规律分析，建立中药治疗卒中后疲劳的循证证据基础。

样本与对象：19 项随机对照试验、1,474 例卒中后疲劳患者；15 个复方、52 味中药。

研究设计：系统评价 + 荟萃分析 + 用药规律分析（PROSPERO 注册 CRD420261356354）。

使用方法：8 大数据库检索至 2026 年 3 月；RevMan 5.4 荟萃分析；漏斗图/Egger 检验；用药频次、性味归经、聚类分析。

主要结果：CHM 显著减轻疲劳严重度，改善生活质量、运动功能与情绪；无显著发表偏倚；高频药物黄芪、当归、川芎；药性温/微温、甘辛味、归脾肝心经，核心治法为补虚与活血化瘀。

局限：原始试验质量与异质性；作者呼吁更大规模多中心 RCT 验证。

临床或科研意义：为中药治疗卒中后疲劳提供初步循证支持，并提炼出核心药物与治法（补虚活血），指导临床处方。

英文原摘要（English Abstract）

[BACKGROUND] Post-stroke fatigue (PSF) is a common and distressing condition among stroke survivors. Chinese herbal medicine (CHM) is frequently utilized in China to manage PSF. However, robust synthesized evidence supporting its efficacy remains limited. This study integrates meta-analysis with medication pattern analysis to establish a comprehensive evidence base for the rational clinical application of CHM in PSF treatment. [METHODS] Relevant RCTs were retrieved from eight databases-including PubMed, Cochrane Library, EMBASE, Web of Science, China National Knowledge Infrastructure Chinese Biomedical Database (SinoMed), Chinese Scientific Journal Database (VIP), and Wanfang-up to March 2026. Meta-analysis was performed using Review Manager 5.4, while funnel plot and Egger's test were utilized to evaluate potential publication bias. Furthermore, we analyzed medication pattern in terms of usage frequency, properties, flavors, meridian tropism, and hierarchical cluster of Traditional Chinese Medicine actions of Chinese medicinal materials. [RESULTS] Nineteen trials involving 1,474 patients were included. Meta-analysis indicated that CHM significantly alleviated fatigue severity, as measured by fatigue severity scale. Evidence also suggested that CHM improved quality of life, motor function, and mood disorders. No significant publication bias was detected. Medication pattern analysis of 15 unique CHM formulas identified 52 Chinese medicinal materials, with high-frequency ingredients including Astragali radix, Angelicae sinensis radix, Chuanxiong rhizoma. The medicinal profiles were characterized by warm or slightly warm natures, sweet and pungent flavors, and tropism toward the spleen, liver, and heart meridians, reflecting core efficacies of tonifying deficiency and acti

vating blood to resolve stasis. [CONCLUSION] This study provides preliminary evidence for the clinical consideration of CHM in the management of post-stroke fatigue and highlights key Chinese medicinal materials and core TCM therapeutic strategies. However, further large-scale, multicenter randomized controlled trials are warranted to strengthen the evidence base and facilitate the integration of CHM into global clinical practice for post-stroke fatigue. [SYSTEMATIC REVIEW REGISTRATION] https://www.crd.york.ac.uk/PROSPERO/view/CRD420261356354.

中文摘要翻译

【背景】卒中后疲劳（PSF）是卒中幸存者常见且困扰的症状。中药（CHM）在中国常用于治疗 PSF，但其疗效的可靠综合证据仍有限。本研究将荟萃分析与用药规律分析相结合，为 CHM 合理用于 PSF 建立全面证据基础。【方法】从 8 个数据库（含 PubMed、Cochrane Library、EMBASE、Web of Science、CNKI、中国生物医学文献数据库 SinoMed、维普 VIP、万方）检索至 2026 年 3 月的相关随机对照试验（RCT）；采用 Review Manager 5.4 行荟萃分析，漏斗图与 Egger 检验评估发表偏倚；并从用药频次、性味、归经与中药功效层次聚类等方面分析用药规律。【结果】纳入 19 项试验、1,474 例患者。荟萃分析显示 CHM 显著减轻疲劳严重度（以疲劳严重度量表测量）；证据还提示 CHM 改善生活质量、运动功能与情绪障碍；未检测到显著发表偏倚。15 个复方、52 味中药的用药规律分析显示高频药物包括黄芪、当归、川芎；药性以温或微温为主、味甘辛、归脾肝心经，反映补虚与活血化瘀的核心治法。【结论】本研究为 PSF 管理中考虑使用 CHM 提供初步证据，并突出关键中药与核心治法；但仍需大规模多中心 RCT 以强化证据基础并推动 CHM 融入 PSF 的全球临床实践。【系统评价注册】PROSPERO CRD420261356354。

第 3 篇（本期第 16 篇）｜草药联合西药治疗卒中后丘脑痛的疗效：系统评价与荟萃分析

英文标题：Effectiveness of adjunctive herbal medicine in the management of post-stroke thalamic pain: a systematic review and meta-analysis

作者：Zhai J, Zhang T, Zhang X, Cheng L, Ma L, Han X, Tan Z, Wang F, Dong X, Zhou L

期刊：Frontiers in Neurology（2026）

DOI：10.3389/fneur.2026.1717558

PMID：42602022

PMC：PMC13473162

原文链接：https://doi.org/10.3389/fneur.2026.1717558

摘要 / 全文可得状态：全文可获取（开放获取，Frontiers）

研究问题：系统评价草药联合西药治疗卒中后丘脑痛的疗效与安全性。

样本与对象：16 项随机对照试验、1,122 例卒中后丘脑痛患者。

研究设计：系统评价 + 荟萃分析（PROSPERO 注册 CRD42024494796）。

使用方法：8 库检索至 2025 年 8 月；随机效应模型合并；GRADE 证据分级；试验序贯分析（TSA）；敏感性/亚组分析。

主要结果：联合治疗总有效率更高（RR=1.38）；VAS、PPI、PRI 显著下降；焦虑与抑郁量表显著改善；不良事件未增加（RR=0.95）；GRADE 证据等级中至极低。

局限：纳入研究全部来自中国；方法学质量限制；证据确定性低（作者自述）。

临床或科研意义：为草药辅助治疗卒中后丘脑痛（镇痛、抗焦虑抑郁）提供循证线索，但需高质量多中心、跨国 RCT 确证。

英文原摘要（English Abstract）

[BACKGROUND] Post-stroke thalamic pain (PSTP) represents one of the most challenging types of refractory central neuropathic pain. The application of herbal medicine alongside Western medicine (WM) has been proposed as a potential therapeutic option for managing PSTP. Nevertheless, its comprehensive effectiveness and safety have yet to be conclusively established. [OBJECTIVE] This study aimed to systematically evaluate the efficacy and safety of herbal medicine combined with WM for the management of PSTP. [METHODS] Eight electronic databases were searched from inception to August 2025 to retrieve randomized controlled trials (RCTs) evaluating combined herbal medicine and WM against WM monotherapy in the management of PSTP. Outcomes included pain intensity measures (VAS, PPI, PRI), anxiety and depression scales (HAMA, SAS, HAMD and SDS), overall treatment effectiveness and adverse events. Sensitivity and subgroup analyses were performed to explore potential sources of heterogeneity. The GRADE framework was used to appraise the strength of evidence for specific results. Trial sequential analysis was carried out with TSA software. [RESULTS] The systematic review encompassed 16 trials, incorporating 1,122 participants. The pooled analysis showed that herbal medicine combined with WM was associated with a higher total effective rate than WM alone (RR = 1.38, 95% CI: 1.28-1.49, p < 0.00001). Compared with WM alone, herbal medicine combined with WM significantly reduced VAS score (MD = -1.50, 95% CI: -1.84 - -1.16, p < 0.00001), PPI score (MD = -1.39, 95% CI: -1.55 - -1.22, p < 0.00001), and PRI score (MD = -2.46, 95% CI: -3.24 - -1.69, p < 0.00001). Combination therapy also effectively reduced anxiety (HAMA: MD = -3.10, 95% CI: -3.53 - -2.67, p < 0.00001; SAS: MD = -6.97, 95%

CI: -7.49 - -6.46, p < 0.00001) and depression (HAMD: MD = -2.26, 95% CI: -2.72 - -1.80, p < 0.00001; SDS: MD = -7.15, 95% CI: -7.66 - -6.65, p < 0.00001). Regarding safety, herbal medicine combined with WM was not associated with an increased incidence of adverse events compared with WM alone (RR = 0.95, 95% CI: 0.55-1.64, p = 0.86). The certainty of evidence assessed using GRADE ranged from moderate to very low. TSA provided additional statistical support for the potential benefit of the combined therapy. [CONCLUSION] Evidence from this systematic review indicates that adjunctive herbal medicine combined with WM may have potential benefits in reducing pain, anxiety, and depression, and improving clinical response in patients with PSTP. However, these findings should be interpreted with caution due to methodological limitations and the exclusive inclusion of studies from China. Further rigorous, multicenter, and multinational trials are needed to confirm these findings. [SYSTEMATIC REVIEW REGISTRATION] The systematic review was registered in PROSPERO (registration number: CRD42024494796).

中文摘要翻译

【背景】卒中后丘脑痛（PSTP）是最难治的顽固性中枢神经病理性疼痛类型之一。草药与西药（WM）联用被提出作为治疗 PSTP 的潜在选择，但其综合疗效与安全性尚未确证。【目的】系统评价草药联合 WM 治疗 PSTP 的疗效与安全性。【方法】检索 8 个电子数据库自建库至 2025 年 8 月的随机对照试验（RCT），比较草药联合 WM 与 WM 单药治疗 PSTP；结局包括疼痛强度（VAS、PPI、PRI）、焦虑与抑郁量表（HAMA、SAS、HAMD、SDS）、总体疗效与不良事件；进行敏感性分析与亚组分析探索异质性来源，用 GRADE 框架评价证据强度，并用 TSA 软件行试验序贯分析。【结果】共纳入 16 项试验、1,122 例受试者。合并分析显示草药联合 WM 的总有效率高于 WM 单药（RR=1.38，95%CI 1.28-1.49，p<0.00001）；与 WM 单药相比，联合治疗显著降低 VAS（MD=-1.50）、PPI（MD=-1.39）与 PRI（MD=-2.46）评分，并有效减轻焦虑（HAMA：MD=-3.10；SAS：MD=-6.97）与抑郁（HAMD：MD=-2.26；SDS：MD=-7.15）。安全性方面，联合治疗不良事件发生率未增加（RR=0.95，95%CI 0.55-1.64，p=0.86）。GRADE 评估的证据确定性为中至极低；TSA 为联合治疗的潜在获益提供额外统计学支持。【结论】本系统评价证据提示草药辅助联合 WM 可能对 PSTP 患者的疼痛、焦虑与抑郁及临床应答有潜在获益；但由于方法学局限及纳入研究全部来自中国，结果应谨慎解读，需更严谨的多中心、跨国试验确认。【系统评价注册】PROSPERO CRD42024494796。

第 4 篇（本期第 17 篇）｜中医药干预老年衰弱与肌少症：研究轨迹与新兴前沿的文献计量与可视化分析

英文标题：Traditional Chinese medicine for frailty and sarcopenia in aging populations: a bibliometric and visualized analysis of research trajectories and emerging frontiers

作者：He X, Sun L, Chen H, Chen Q

期刊：Frontiers in Aging（2026）

DOI：10.3389/fragi.2026.1854710

PMID：42602223

PMC：PMC13473409

原文链接：https://doi.org/10.3389/fragi.2026.1854710

摘要 / 全文可得状态：全文可获取（开放获取，Frontiers）

研究问题：对中医药干预衰弱与肌少症的研究进行文献计量与可视化分析，描绘研究轨迹与新兴前沿。

样本与对象：405 篇文献（2011—2026 年），来源于 Web of Science 核心合集。

研究设计：文献计量/可视化分析研究。

使用方法：CiteSpace、VOSviewer、bibliometrix；关键词共现/增长/突现、主题图谱与演化、共被引分析（剔除检索词以避免偏倚）。

主要结果：2019 年后产出激增，2025 年峰值 77 篇；中国主导（910 作者次），美日次之；主题聚类涵盖运动/衰老、RCT、跌倒/康复、证据综合、营养/炎症；前沿为网络药理学、分子对接、人参养荣汤与营养。

局限：单一数据库（WoS）来源；文献计量方法固有局限（如覆盖范围、时滞）。

临床或科研意义：提供中医药老年衰弱/肌少症研究的结构化证据图谱，明确未来研究优先方向，助力老年照护转化。

英文原摘要（English Abstract）

[BACKGROUND] By 2050, the proportion of people aged 65 and older is projected to reach 16% globally, up from roughly 10% in 2022. Frailty and sarcopenia are among the most clinically consequential age-related conditions, independently associated with falls, hospitalization, and death. Traditional Chinese medicine (TCM)-encompassing herbal formulas, acupuncture, tai chi, and qigong-has shown therapeutic potential for both conditions, yet no systematic bibliometric overview of this research area exists. [METHODS] Publications on TCM interventions for frailty and sarcopenia were retrieved from the Web of Science Core Collection on 14 March 2026. After a four-phase screening (identification, document-type screening, title/abstract relevance screening, and inclusion), 405 publications were retained. Bibliometric and visualization analyses were performed using CiteSpace (6.2.R6), VOSviewer (1.6.20), and the R package bibliometrix (4.3.0). To avoid tautological bias, all Boolean search terms were removed from the keyword field before every keyword-based analysis (co-occurrence, growth, burst detection, thematic mapping, and thematic evolution). [RESULTS] A total of 405 publications from 2011 to 2026 were included. Annual output grew sharply after 2019 and peaked at 77 publications in 2025. China was the overwhelmingly dominant contributor (910 author appearances), followed by the USA (152) and Japan (131). With search terms excluded, keyword co-occurrence resolved into interpretable clusters: exercise/physical activity/aging; randomized controlled trials of muscle strength and physical function; falls, balance and rehabilitation; evidence synthesis (systematic review/meta-analysis); and cachexia/nutrition/skeletal-muscle inflammation. Burst detection showed early activity in f

alls, balance, elderly, and exercise (2011-2018) shifting toward network pharmacology, molecular docking, ninjin'yoeito, and nutrition (2020-2026). Co-citation analysis identified the seminal frailty-phenotype study as the foundational reference, with a strong tai-chi fall-prevention trial base and the EWGSOP/AWGS sarcopenia consensus definitions as intellectual pillars. [CONCLUSION] TCM research on frailty and sarcopenia has grown substantially, particularly since 2019, with China as the primary driver and Japan and the USA as secondary contributors. Network pharmacology, nutrition-based intervention science, and oxidative-stress/inflammation mechanisms represent the most promising emerging frontiers. These findings provide a structured evidence map for prioritizing future research and translational efforts in TCM-based geriatric care.

中文摘要翻译

【背景】预计到 2050 年全球 65 岁及以上人口比例将从 2022 年的约 10% 升至 16%。衰弱与肌少症是临床后果最严重的年龄相关疾病之一，与跌倒、住院和死亡独立相关。中医药（TCM）——涵盖中药复方、针灸、太极与气功——对这两种疾病显示出治疗潜力，但该领域尚无系统的文献计量综述。【方法】2026 年 3 月 14 日从 Web of Science 核心合集检索中医药干预衰弱与肌少症的文献，经四阶段筛选（识别、文献类型筛选、题录/摘要相关性筛选、纳入）后保留 405 篇；采用 CiteSpace（6.2.R6）、VOSviewer（1.6.20）与 R 包 bibliometrix（4.3.0）进行文献计量与可视化分析；为避免同义反复偏倚，在每次基于关键词的分析（共现、增长、突现、主题图谱、主题演化）前均从关键词字段剔除所有布尔检索词。【结果】共纳入 2011—2026 年 405 篇文献。2019 年后年产量激增，2025 年达峰值 77 篇。中国为绝对主导贡献者（910 人次作者出现），美国（152）与日本（131）次之。剔除检索词后，关键词共现解析为可解释的聚类：运动/体力活动/衰老；肌力与身体功能的随机对照试验；跌倒/平衡/康复；证据综合（系统评价/荟萃分析）；恶病质/营养/骨骼肌炎症。突现检测显示早期（2011—2018）集中于跌倒、平衡、老年与运动，2020—2026 年转向网络药理学、分子对接、人参养荣汤与营养。共被引分析将奠基性衰弱表型研究确定为根本文献，以太极拳防跌倒试验为基础，并以 EWGSOP/AWGS 肌少症共识定义为知识支柱。【结论】中医药衰弱与肌少症研究自 2019 年以来显著增长，中国为主要驱动力，日本与美国为次要贡献者；网络药理学、营养干预科学与氧化应激/炎症机制是最有前景的新兴前沿。这些发现为中医药老年照护的未来研究与转化提供结构化的证据图谱。

第四部分 · 中医药相关领域（肠道菌群、天然产物与真实世界）

第 1 篇（本期第 18 篇）｜肾脏疾病中的肠道菌群与肠-肾轴：天然产物的治疗潜力与展望

英文标题：Gut microbiota and gut-kidney axis in kidney diseases: therapeutic potential and perspectives of natural products

作者：Wang Q, Zhang J, Chen R, Song J, Lv J, Zhou Z, Dai L

期刊：Frontiers in Pharmacology（2026）

DOI：10.3389/fphar.2026.1888944

PMID：42602032

PMC：PMC13473280

原文链接：https://doi.org/10.3389/fphar.2026.1888944

摘要 / 全文可得状态：全文可获取（开放获取，Frontiers）

研究问题：总结肠道菌群紊乱与肾脏疾病的病理联系，以及天然产物（含中药复方）经肠-肾轴发挥肾脏保护作用的机制与潜力。

样本与对象：综述研究（基于既往文献）。

研究设计：叙述性综述。

使用方法：系统归纳肠-肾轴机制（尿毒症毒素、SCFA、信号通路）与天然产物干预证据。

主要结果：CKD 存在显著菌群失调与尿毒症毒素蓄积、SCFA 减少；通过 RAS、TLR4、AhR、NF-κB、Nrf2、NLRP3、铁死亡等通路促进肾损伤；天然多糖、中药复方、植物多酚可重塑菌群、修复肠屏障、调节肠-肾轴稳态。

局限：综述性质，机制与临床转化的直接证据需更多干预研究验证。

临床或科研意义：提出靶向肠微生态与肠-肾轴防治 CKD、改善透析预后的新策略，为中医药等天然产物的肾病应用提供理论框架。

英文原摘要（English Abstract）

Gut microbiota exert core regulatory effects on systemic metabolic homeostasis and immune balance under physiological and pathological conditions. Marked gut dysbiosis occurs during the progression of chronic kidney disease (CKD), characterized by abnormal enrichment of opportunistic pathogens and depletion of beneficial commensal bacteria. This pathological alteration leads to excessive accumulation of uremic toxins including indoxyl sulfate, p-cresyl sulfate and trimethylamine N-oxide (TMAO), as well as sharp reductions in the synthesis of intestinal protective metabolites such as short-chain fatty acids (SCFAs) and indole-3-aldehyde. The imbalance between harmful and protective metabolites persistently triggers renal inflammatory activation and interstitial fibrosis via activating multiple signaling pathways, including the renin-angiotensin system, oxidative stress, Toll-like receptor 4, aryl hydrocarbon receptor, IκB/NF-κB, Keap1/Nrf2, NLRP3 inflammasome and ferroptosis. This review systematically summarizes the pathological correlations between gut microbiota disturbance and various renal disorders, namely diabetic kidney disease, membranous nephropathy, lupus nephritis, IgA nephropathy, hypertension-associated nephropathy and dialysis-related renal injury, and clarifies the universal mechanisms and disease-specific characteristics underlying gut-kidney axis-mediated progression of different subtypes of kidney diseases. Natural products represented by natural polysaccharides, traditional Chinese medicine formulas and plant polyphenols are capable of remodeling gut microbiota composition, repairing intestinal mucosal barrier function, balancing microbial metabolic profiles and regulating gut-kidney axis homeostasis, thereby exerting renal and multi-organ protective

effects in patients with CKD and dialysis-dependent individuals. Targeted modulation of intestinal microecology and intervention against gut-kidney axis dysfunction using natural products provide novel strategies for early prevention and control of CKD, disease progression retardation and prognosis improvement in dialysis patients, and also lay a theoretical foundation for the development and clinical translational application of novel therapeutic targets for kidney diseases.

中文摘要翻译

肠道菌群在生理与病理条件下对全身代谢稳态与免疫平衡发挥核心调控作用。慢性肾脏病（CKD）进展过程中出现显著肠道菌群失调，表现为机会致病菌异常富集与有益共生菌减少；这一病理改变导致硫酸吲哚酚、对甲酚硫酸盐、三甲胺氧化物（TMAO）等尿毒症毒素过度蓄积，同时短链脂肪酸（SCFA）与吲哚-3-甲醛等肠道保护性代谢物合成锐减。有害与保护性代谢物的失衡通过激活肾素-血管紧张素系统、氧化应激、Toll 样受体 4、芳香烃受体、IκB/NF-κB、Keap1/Nrf2、NLRP3 炎症小体及铁死亡等多条信号通路，持续触发肾脏炎症激活与间质纤维化。本综述系统总结了肠道菌群紊乱与糖尿病肾病、膜性肾病、狼疮性肾炎、IgA 肾病、高血压相关肾病及透析相关肾损伤等各类肾脏疾病的病理联系，阐明肠-肾轴介导不同亚型肾病进展的共性机制与疾病特异性特征。以天然多糖、中药复方与植物多酚为代表的天然产物能够重塑肠道菌群组成、修复肠黏膜屏障功能、平衡微生物代谢谱并调节肠-肾轴稳态，从而在 CKD 患者及依赖透析者中发挥肾脏与多器官保护作用。利用天然产物靶向调节肠道微生态、干预肠-肾轴功能障碍，为 CKD 的早期防治、延缓疾病进展与改善透析患者预后提供了新策略，也为肾脏疾病新治疗靶点的开发与临床转化奠定了理论基础。

第 2 篇（本期第 19 篇）｜肠道菌群与缺血性卒中：从卒中前菌群失调和急性期变化到治疗应用

英文标题：Gut Microbiota and Ischemic Stroke: From Pre-Stroke Dysbiosis and Acute-Phase Changes to Therapeutic Applications

作者：Weng R, Dong G, Tang J, Zhao Y

期刊：Brain and Behavior（2026）

DOI：10.1002/brb3.71547

PMID：42603266

PMC：暂无

原文链接：https://doi.org/10.1002/brb3.71547

摘要 / 全文可得状态：开放获取全文（Brain and Behavior 为全开放获取期刊，Wiley）

研究问题：总结菌群-肠-脑轴在缺血性卒中发病与恢复中的作用，梳理从危险因素到治疗应用的研究现状。

样本与对象：综述研究（基于既往文献）。

研究设计：叙述性综述。

使用方法：综合文献，从发病风险、菌群动态、宿主因素、并发症与候选干预（含中医药）等方面归纳。

主要结果：菌群失调经 TMAO、全身炎症等成为卒中危险因素；卒中后产 SCFA 菌减少、促炎菌扩张；并发症与持续失调相关；益生菌/益生元、FMT、SCFA、中医药与神经调控在临床前模型显示神经保护；小型试验中益生菌与膳食纤维有适度获益。

局限：人类临床证据初步；FMT、SCFA 补充与神经调控需大样本 RCT 验证。

临床或科研意义：强调肠道菌群作为卒中可干预靶点的潜力，并提出个体化菌群分析指导卒中辅助治疗的前景，中医药被列为候选干预之一。

英文原摘要（English Abstract）

[PURPOSE] Ischemic stroke poses a major global health burden, and growing evidence points to the microbiota-gut-brain axis as an important contributor to stroke pathophysiology and recovery. The purpose of this review is to summarize current knowledge on bidirectional gut-brain communication in stroke, establishing gut dysbiosis as an upstream risk factor for stroke onset and examining microbiota dynamics across acute and chronic phases. [METHOD] A comprehensive review of the current literature was conducted to synthesize existing evidence on the mechanisms of gut-brain communication, the influence of host factors, post-stroke complications, and candidate therapeutic interventions targeting the MGBA in ischemic stroke. [FINDING] Gut dysbiosis acts as a risk factor for stroke through TMAO-mediated atherothrombosis, systemic inflammatory priming, and comorbidity-associated dysbiotic pre-conditioning. Following a stroke, dysbiosis is characterized by a depletion of short-chain fatty acid (SCFA)-producing taxa and an expansion of pro-inflammatory bacteria, particularly Proteobacteria and Enterobacteriaceae. Host factors (age, sex, genetics, and comorbidities) shape microbiota signatures and influence outcomes. Furthermore, post-stroke complications-including cognitive impairment, depression, stroke-associated pneumonia, and gastrointestinal dysfunction-are intimately linked to persistent dysbiosis. Mechanistically, the gut microbiota modulates stroke outcomes through immune regulation, metabolite signaling, blood-brain barrier integrity, and vagal pathways. Candidate therapeutic interventions (probiotics/prebiotics, fecal microbiota transplantation, SCFA supplementation, traditional Chinese medicine, and neuromodulation) demonstrate promising neuroprotective and recovery-en

hancing effects, predominantly in preclinical models. [CONCLUSION] While targeted interventions like probiotics and dietary fiber supplementation have shown modest benefits in small clinical trials, human clinical evidence remains largely preliminary. The translation of FMT, SCFA supplementation, and neuromodulatory approaches to clinical practice requires validation through rigorous, adequately powered randomized controlled trials. Future precision microbiome medicine demands individualized profiling and phenotype-specific interventions to establish microbiota-targeted strategies as viable adjunctive stroke therapies.

中文摘要翻译

【目的】缺血性卒中造成重大全球健康负担，越来越多的证据表明菌群-肠-脑轴是卒中病理生理与恢复的重要参与者。本综述旨在总结卒中中肠脑双向通讯的研究现状，确立肠道菌群失调为卒中发生的上游危险因素，并考察急性期与慢性期菌群动态。【方法】对现有文献进行综合回顾，整合肠脑通讯机制、宿主因素影响、卒中后并发症及靶向菌群-肠-脑轴（MGBA）的候选治疗干预证据。【结果】肠道菌群失调通过 TMAO 介导的动脉粥样硬化性血栓形成、全身炎症启动及合并症相关的失调预适应而成为卒中危险因素。卒中后菌群失调表现为产短链脂肪酸（SCFA）菌群减少与促炎菌（尤其变形菌门、肠杆菌科）扩张。宿主因素（年龄、性别、遗传与合并症）塑造菌群特征并影响结局。此外，认知障碍、抑郁、卒中相关肺炎与胃肠功能障碍等卒中后并发症与持续菌群失调密切相关。机制上，肠道菌群通过免疫调节、代谢物信号、血脑屏障完整性与迷走通路调节卒中结局。益生菌/益生元、粪菌移植（FMT）、SCFA 补充、中医药与神经调控等候选干预在临床前模型中显示出有前景的神经保护与恢复促进作用。【结论】尽管益生菌与膳食纤维补充等靶向干预在小规模临床试验中显示出适度获益，人体临床证据仍大体处于初步阶段。FMT、SCFA 补充与神经调控方法的临床转化需经严格、把握度充分的随机对照试验验证。未来精准微生物组医学要求个体化谱系分析与表型特异干预，方能使靶向菌群策略成为可行的卒中辅助治疗。

第 3 篇（本期第 20 篇）｜影响乳腺癌患者完成针灸疗程的因素：来自 NCI 指定综合癌症中心的真实世界数据

英文标题：Factors influencing acupuncture regimen completion by breast cancer patients: real-world data from an NCI-designated comprehensive cancer center

作者：Zelaya MG, Borjigin M, Lahiji R, Fung G, Bausum A, Melikian M, Catic A, Mumford S, Slomik H, Nguyen J, Patil D, Suk R, Smith-Graziani D, Kalinsky K, Master VA

期刊：Supportive Care in Cancer（2026）

DOI：10.1007/s00520-026-11098-8

PMID：42601524

PMC：暂无

原文链接：https://doi.org/10.1007/s00520-026-11098-8

摘要 / 全文可得状态：元数据与摘要可得（PubMed）；全文需订阅（未检索到开放全文）

研究问题：识别乳腺癌患者未完成针灸疗程的相关因素，找出可改善的依从性障碍。

样本与对象：563 例开始针灸治疗的乳腺癌患者（2022 年 5 月—2025 年 3 月，单中心）。

研究设计：单中心回顾性真实世界研究。

使用方法：疗程完成定义为≥8 次；分析人口学、临床与 PROMIS-29；逐步多变量 logistic 回归。

主要结果：268 例（47.6%）完成疗程；非白人族裔（OR=0.64）、晚期分期（OR=0.55）、吸烟史（OR=0.63）、中重度焦虑（OR=0.67）与较低完成率独立相关。

局限：单中心回顾性设计，结果外推性有限。

临床或科研意义：提示针灸依从性受种族、分期、焦虑与吸烟等因素影响，可据此设计个性化干预与整合心理支持以改善依从性。

英文原摘要（English Abstract）

[BACKGROUND] Acupuncture is a complementary medicine therapy increasingly used to manage cancer-related symptoms. Despite its demonstrated efficacy, adherence rates among patients with breast cancer remain suboptimal. This study aimed to identify factors associated with non-completion of acupuncture regimens within a single institutional integrative oncology program to identify modifiable barriers to service utilization. [METHODS] Patients with breast cancer who began acupuncture treatment at an NCI-designated comprehensive cancer center between May 2022 and March 2025 were retrospectively included in this study. Regimen completion was defined as attending a minimum of eight sessions. Demographic, clinical, and patient-reported outcomes (PROMIS-29) were analyzed. Stepwise multivariable logistic regression was used to identify predictors of regimen completion. [RESULTS] Of 563 patients, 268 (47.6%) completed the recommended acupuncture regimen. In multivariable analysis, non-White race (OR 0.64, 95% CI 0.45-0.92, p = 0.016), advanced cancer stage (defined as stages 3-4; OR 0.55, 95% CI 0.37-0.82, p = 0.003), smoking history (OR 0.63, 95% CI 0.41-0.95, p = 0.029), and moderate-to-severe anxiety (OR 0.67, 95% CI 0.45-1.00, p = 0.048) were independently associated with lower odds of regimen completion. [CONCLUSION] Racial disparities, clinical stage, baseline anxiety, and smoking history were significantly associated with lowered acupuncture adherence in patients with breast cancer. Tailored interventions including early identification of at-risk patients and integrated mental health support may be evaluated to improve adherence to integrative therapies.

中文摘要翻译

【背景】针灸是日益广泛用于管理癌症相关症状的补充医学疗法。尽管其疗效已被证实，乳腺癌患者的依从率仍不理想。本研究旨在识别单中心整合肿瘤学项目中与乳腺癌患者未完成针灸疗程相关的因素，找出可改变的服务利用障碍。【方法】回顾性纳入 2022 年 5 月至 2025 年 3 月在 NCI 指定综合癌症中心开始针灸治疗的乳腺癌患者；疗程完成定义为至少接受 8 次治疗。分析人口学、临床与患者报告结局（PROMIS-29）资料，采用逐步多变量 logistic 回归识别疗程完成的预测因素。【结果】563 例患者中 268 例（47.6%）完成了推荐针灸疗程。多变量分析中，非白人族裔（OR=0.64，95%CI 0.45-0.92，p=0.016）、晚期癌症（3-4 期；OR=0.55，95%CI 0.37-0.82，p=0.003）、吸烟史（OR=0.63，95%CI 0.41-0.95，p=0.029）及中重度焦虑（OR=0.67，95%CI 0.45-1.00，p=0.048）与疗程完成率较低独立相关。【结论】种族差异、临床分期、基线焦虑与吸烟史与乳腺癌患者针灸依从性降低显著相关。可评估针对高危患者的早期识别与整合心理健康支持等个性化干预，以改善整合疗法依从性。

三、重要说明与免责声明

1. 本速递所有文献条目均来源于公开可访问的学术数据库，题录、DOI、PMID 与摘要均以 PubMed/Crossref 原始记录为准，未虚构任何文献。

2. 中文摘要翻译为自动直译加人工整理，仅供快速阅读参考；引用或决策请以英文原文为准。

3. “主要结果”“局限”等条目严格基于已获取的摘要信息撰写；摘要未明示的内容已标注“需查全文”，未作推测性补充。

4. 部分期刊全文需订阅，标注为“全文需订阅”的文献仅保证题录与摘要可得。

5. 本速递不构成临床诊疗建议；中医药方案请在有资质的中医师/医师指导下使用。

—— 中医药每日文献速递 · 2026-08-16 · 完 ——